<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230000918</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>156</s160></s100><s200><s210>1</s210><s211>1178</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 1gctccggtgc ccgtcagtgg gcagagcgca catcgcccac agtccccgag aagttggggg     60gaggggtcgg caattgaacc ggtgcctaga gaaggtggcg cggggtaaac tgggaaagtg    120atgtcgtgta ctggctccgc ctttttcccg agggtggggg agaaccgtat ataagtgcag    180tagtcgccgt gaacgttctt tttcgcaacg ggtttgccgc cagaacacag gtaagtgccg    240tgtgtggttc ccgcgggcct ggcctcttta cgggttatgg cccttgcgtg ccttgaatta    300cttccacctg gctgcagtac gtgattcttg atcccgagct tcgggttgga agtgggtggg    360agagttcgag gccttgcgct taaggagccc cttcgcctcg tgcttgagtt gaggcctggc    420ctgggcgctg gggccgccgc gtgcgaatct ggtggcacct tcgcgcctgt ctcgctgctt    480tcgataagtc tctagccatt taaaattttt gatgacctgc tgcgacgctt tttttctggc    540aagatagtct tgtaaatgcg ggccaagatc tgcacactgg tatttcggtt tttggggccg    600cgggcggcga cggggcccgt gcgtcccagc gcacatgttc ggcgaggcgg ggcctgcgag    660cgcggccacc gagaatcgga cgggggtagt ctcaagctgg ccggcctgct ctggtgcctg    720gcctcgcgcc gccgtgtatc gccccgccct gggcggcaag gctggcccgg tcggcaccag    780ttgcgtgagc ggaaagatgg ccgcttcccg gccctgctgc agggagctca aaatggagga    840cgcggcgctc gggagagcgg gcgggtgagt cacccacaca aaggaaaagg gcctttccgt    900cctcagccgt cgcttcatgt gactccactg agtaccgggc gccgtccagg cacctcgatt    960agttctcgag cttttggagt acgtcgtctt taggttgggg ggaggggttt tatgcgatgg   1020agtttcccca cactgagtgg gtggagactg aagttaggcc agcttggcac ttgatgtaat   1080tctccttgga atttgccctt tttgagtttg gatcttggtt cattctcaag cctcagacag   1140tggttcaaag tttttttctt ccatttcagg tgtcgtga                           1178</s400><s200><s210>2</s210><s211>507</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 2ctaccgggta ggggaggcgc ttttcccaag gcagtctgga gcatgcgctt tagcagcccc     60gctgggcact tggcgctaca caagtggcct ctggcctcgc acacattcca catccaccgg    120taggcgccaa ccggctccgt tctttggtgg ccccttcgcg ccaccttcta ctcctcccct    180agtcaggaag ttcccccccg ccccgcagct cgcgtcgtgc aggacgtgac aaatggaagt    240agcacgtctc actagtctcg tgcagatgga cagcaccgct gagcaatgga agcgggtagg    300cctttggggc agcggccaat agcagctttg ctccttcgct ttctgggctc agaggctggg    360aaggggtggg tccgggggcg ggctcagggg cgggctcagg ggcggggcgg gcgcccgaag    420gtcctccgga ggcccggcat tctgcacgct tcaaaagcgc acgtctgccg cgctgttctc    480ctcttcctca tctccgggcc tttcgac                                        507</s400><s200><s210>3</s210><s211>266</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 3ggtatcgata agcttgatat cgaattagga ggaaaaactg tttcatacag aaggcgtcaa     60ttaggaggaa aaactgtttc atacagaagg cgtcaattag gaggaaaaac tgtttcatac    120agaaggcgtc aattggtccc atcgaattag gaggaaaaac tgtttcatac agaaggcgtc    180aattaggagg aaaaactgtt tcatacagaa ggcgtcaatt aggaggaaaa actgtttcat    240acagaaggcg tcaattggtc ccggga                                         266</s400><s200><s210>4</s210><s211>113</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 4cattttgaca cccccataat atttttccag aattaacagt ataaattgca tctcttgttc     60aagagttccc tatcactctc tttaatcact actcacagta acctcaactc ctg           113</s400><s200><s210>5</s210><s211>66</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 5atggacatgc gagttcctgc ccaactgctt ggccttcttt tgctctggct gccaggagcc     60aagtgc                                                                66</s400><s200><s210>6</s210><s211>22</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 6Met Asp Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Leu Trp1               5                   10                  15Leu Pro Gly Ala Lys Cys            20</s400><s200><s210>7</s210><s211>57</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 7atggagtttg ggctgagctg ggttttcctc gttgctcttt ttagaggtgt acagtgt        57</s400><s200><s210>8</s210><s211>19</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 8Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu Phe Arg Gly1               5                   10                  15Val Gln Cys</s400><s200><s210>9</s210><s211>207</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 9accacgacgc cagcgccgcg accaccaaca ccggcgccca ccatcgcgtc gcagcccctg     60tccctgcgcc cagaggcgtg ccggccagcg gcggggggcg cagtgcacac gagggggctg    120gacttcgcct gtgatatcta catctgggcg cccttggccg ggacttgtgg ggtccttctc    180ctgtcactgg ttatcaccct ttactgc                                        207</s400><s200><s210>10</s210><s211>69</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 10Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala1               5                   10                  15Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly            20                  25                  30Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile        35                  40                  45Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val    50                  55                  60Ile Thr Leu Tyr Cys65</s400><s200><s210>11</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 11agagtgaagt tcagcaggag cgcagacgcc cccgcgtaca agcagggcca gaaccagctc     60tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa gagacgtggc    120cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat    180gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc    240cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc    300tacgacgccc ttcacatgca ggccctgccc cctcgc                              336</s400><s200><s210>12</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 12Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly1               5                   10                  15Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr            20                  25                  30Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys        35                  40                  45Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys    50                  55                  60Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg65                  70                  75                  80Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala                85                  90                  95Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg            100                 105                 110</s400><s200><s210>13</s210><s211>126</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 13aaacggggca gaaagaaact cctgtatata ttcaaacaac catttatgag accagtacaa     60actactcaag aggaagatgg ctgtagctgc cgatttccag aagaagaaga aggaggatgt    120gaactg                                                               126</s400><s200><s210>14</s210><s211>42</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 14Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met1               5                   10                  15Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe            20                  25                  30Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu        35                  40</s400><s200><s210>15</s210><s211>399</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 15gccccaacca gctcaagtac taagaagaca cagctgcagc tggagcacct gctgctggac     60ctgcagatga tcctgaacgg catcaacaac tacaagaacc ccaagctgac ccgcatgctg    120accttcaagt tctacatgcc caagaaggcc accgagctga agcacctgca gtgcctggag    180gaggagctga agcccctgga ggaggtgctg aacctggccc agagcaagaa cttccacctg    240cgcccccgcg acctgatcag caacatcaac gtgatcgtgc tggagctgaa gggcagcgag    300accaccttca tgtgcgagta cgccgacgag accgccacca tcgtggagtt cctgaaccgc    360tggatcacct tctgccagag catcatcagc accctgacc                           399</s400><s200><s210>16</s210><s211>133</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 16Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His1               5                   10                  15Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>17</s210><s211>1530</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 17atctgggagc tgaagaagga cgtgtacgtg gtggagctgg actggtaccc cgacgccccc     60ggcgagatgg tggtattaac ctgcgacacc ccagaggaag acggcatcac ctggaccctg    120gaccagtcaa gcgaggtgct gggtagcggc aagaccctga ccatccaggt gaaggagttc    180ggcgacgccg gccagtacac ctgccacaag ggcggcgagg tgctgagcca cagcctactg    240cttctccaca agaaggagga cggcatctgg agcaccgaca tcctgaagga ccagaaggag    300cccaagaaca agaccttcct gcgctgcgag gccaagaatt actcaggacg attcacctgc    360tggtggctga ccaccatcag caccgacctg accttcagcg tgaagagcag ccgcggcagc    420agcgaccccc agggcgtgac ctgcggcgcc gccaccctga gcgccgagcg cgtgcgcggc    480gacaacaagg agtacgagta cagcgtggag tgccaggagg acagcgcctg ccccgccgcc    540gaggagagcc tgcccatcga ggtgatggtg gacgccgtgc acaagctgaa gtacgagaac    600tacaccagca gcttcttcat ccgcgacatc atcaagcccg acccccccaa gaacctgcag    660ctgaagcccc tgaagaacag ccgccaggtg gaggtgagct gggagtaccc cgacacctgg    720agcacccccc acagctactt cagcctgacc ttctgcgtgc aggtgcaggg caagagcaag    780cgcgagaaga aggaccgcgt gttcaccgac aagaccagcg ccaccgtgat ctgccgcaag    840aatgcgagca tcagcgtgcg cgcccaggac cgctactaca gcagcagctg gagcgagtgg    900gccagcgtgc cctgcagcgg aggtggcggt ggaggcagcc gcaacctgcc cgtggccacc    960cccgaccccg gcatgttccc ctgcctgcac cacagccaga acctgctgcg cgccgtgagc   1020aacatgctgc agaaggcccg ccagaccctg gagttctacc cctgcaccag cgaggagatc   1080gaccacgagg acatcaccaa ggacaagacc agcaccgtgg aggcctgcct gcccctggag   1140ctgaccaaga acgagagctg tctgaacagc agagagacta gcttcatcac taacggcagc   1200tgcctagcca gccgcaagac cagcttcatg atggccctgt gcctgagcag catctacgag   1260gacctgaaga tgtaccaggt ggagttcaag accatgaacg ccaagctgct gatggacccc   1320aagcgccaga tcttcctgga ccagaacatg ctggccgtga tcgacgagct gatgcaggcc   1380ctgaacttca acagcgagac cgtgccccag aagagcagcc tggaggagcc cgacttctac   1440aagaccaaga tcaagctgtg catcctgctg cacgccttcc gcatccgcgc cgtgaccatc   1500gaccgcgtga tgagctacct gaacgcatca                                    1530</s400><s200><s210>18</s210><s211>510</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 18Ile Trp Glu Leu Lys Lys Asp Val Tyr Val Val Glu Leu Asp Trp Tyr1               5                   10                  15Pro Asp Ala Pro Gly Glu Met Val Val Leu Thr Cys Asp Thr Pro Glu            20                  25                  30Glu Asp Gly Ile Thr Trp Thr Leu Asp Gln Ser Ser Glu Val Leu Gly        35                  40                  45Ser Gly Lys Thr Leu Thr Ile Gln Val Lys Glu Phe Gly Asp Ala Gly    50                  55                  60Gln Tyr Thr Cys His Lys Gly Gly Glu Val Leu Ser His Ser Leu Leu65                  70                  75                  80Leu Leu His Lys Lys Glu Asp Gly Ile Trp Ser Thr Asp Ile Leu Lys                85                  90                  95Asp Gln Lys Glu Pro Lys Asn Lys Thr Phe Leu Arg Cys Glu Ala Lys            100                 105                 110Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp Leu Thr Thr Ile Ser Thr        115                 120                 125Asp Leu Thr Phe Ser Val Lys Ser Ser Arg Gly Ser Ser Asp Pro Gln    130                 135                 140Gly Val Thr Cys Gly Ala Ala Thr Leu Ser Ala Glu Arg Val Arg Gly145                 150                 155                 160Asp Asn Lys Glu Tyr Glu Tyr Ser Val Glu Cys Gln Glu Asp Ser Ala                165                 170                 175Cys Pro Ala Ala Glu Glu Ser Leu Pro Ile Glu Val Met Val Asp Ala            180                 185                 190Val His Lys Leu Lys Tyr Glu Asn Tyr Thr Ser Ser Phe Phe Ile Arg        195                 200                 205Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn Leu Gln Leu Lys Pro Leu    210                 215                 220Lys Asn Ser Arg Gln Val Glu Val Ser Trp Glu Tyr Pro Asp Thr Trp225                 230                 235                 240Ser Thr Pro His Ser Tyr Phe Ser Leu Thr Phe Cys Val Gln Val Gln                245                 250                 255Gly Lys Ser Lys Arg Glu Lys Lys Asp Arg Val Phe Thr Asp Lys Thr            260                 265                 270Ser Ala Thr Val Ile Cys Arg Lys Asn Ala Ser Ile Ser Val Arg Ala        275                 280                 285Gln Asp Arg Tyr Tyr Ser Ser Ser Trp Ser Glu Trp Ala Ser Val Pro    290                 295                 300Cys Ser Gly Gly Gly Gly Gly Gly Ser Arg Asn Leu Pro Val Ala Thr305                 310                 315                 320Pro Asp Pro Gly Met Phe Pro Cys Leu His His Ser Gln Asn Leu Leu                325                 330                 335Arg Ala Val Ser Asn Met Leu Gln Lys Ala Arg Gln Thr Leu Glu Phe            340                 345                 350Tyr Pro Cys Thr Ser Glu Glu Ile Asp His Glu Asp Ile Thr Lys Asp        355                 360                 365Lys Thr Ser Thr Val Glu Ala Cys Leu Pro Leu Glu Leu Thr Lys Asn    370                 375                 380Glu Ser Cys Leu Asn Ser Arg Glu Thr Ser Phe Ile Thr Asn Gly Ser385                 390                 395                 400Cys Leu Ala Ser Arg Lys Thr Ser Phe Met Met Ala Leu Cys Leu Ser                405                 410                 415Ser Ile Tyr Glu Asp Leu Lys Met Tyr Gln Val Glu Phe Lys Thr Met            420                 425                 430Asn Ala Lys Leu Leu Met Asp Pro Lys Arg Gln Ile Phe Leu Asp Gln        435                 440                 445Asn Met Leu Ala Val Ile Asp Glu Leu Met Gln Ala Leu Asn Phe Asn    450                 455                 460Ser Glu Thr Val Pro Gln Lys Ser Ser Leu Glu Glu Pro Asp Phe Tyr465                 470                 475                 480Lys Thr Lys Ile Lys Leu Cys Ile Leu Leu His Ala Phe Arg Ile Arg                485                 490                 495Ala Val Thr Ile Asp Arg Val Met Ser Tyr Leu Asn Ala Ser            500                 505                 510</s400><s200><s210>19</s210><s211>342</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 19aactgggtga acgtgatcag cgacctgaag aagatcgagg acctgatcca gagcatgcac     60atcgacgcca ccctgtacac cgagagcgac gtgcacccca gctgcaaggt gaccgccatg    120aagtgcttcc tgctggagct gcaggtgatc agcctggaga gcggcgacgc cagcatccac    180gacaccgtgg agaacctgat catcctggcc aacaacagcc tgagcagcaa cggcaacgtg    240accgagagcg gctgcaagga gtgcgaggag ctggaggaga agaacatcaa ggagttcctg    300cagagcttcg tgcacatcgt gcagatgttc atcaacacca gc                       342</s400><s200><s210>20</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 20Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu Ile1               5                   10                  15Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp Val His            20                  25                  30Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu Leu Gln        35                  40                  45Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr Val Glu    50                  55                  60Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn Gly Asn Val65                  70                  75                  80Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu Glu Glu Lys Asn Ile                85                  90                  95Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met Phe Ile Asn            100                 105                 110Thr Ser</s400><s200><s210>21</s210><s211>471</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 21tacttcggca agctggagag caagctgagc gtgatccgca acctgaacga ccaggtgctg     60ttcatcgacc agggcaaccg ccccctgttc gaggacatga ccgacagcga ctgccgcgac    120aacgcccccc gcaccatctt catcatcagc atgtacaagg acagccagcc ccgcggcatg    180gccgtgacca tcagcgtgaa gtgcgagaag atcagcaccc tgagctgcga gaacaagatc    240atcagcttca aggagatgaa cccccccgac aacatcaagg acaccaagag cgacatcatc    300ttcttccagc gcagcgtgcc cggccacgac aacaagatgc agttcgagag cagcagctac    360gagggctact tcctggcctg cgagaaggag cgcgacctgt tcaagctgat cctgaagaag    420gaggacgagc tgggcgaccg cagcatcatg ttcaccgtgc agaacgagga c             471</s400><s200><s210>22</s210><s211>157</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 22Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn1               5                   10                  15Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp            20                  25                  30Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile        35                  40                  45Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile    50                  55                  60Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile65                  70                  75                  80Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys                85                  90                  95Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys            100                 105                 110Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu        115                 120                 125Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu    130                 135                 140Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp145                 150                 155</s400><s200><s210>23</s210><s211>726</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 23gacgtggtga tgacccagag ccccctgagc ctgcccgtga cccccggcga gcccgccagc     60atcagctgcc gcagcagcca gagcctggtg cacagcaacc gcaacaccta cctgcactgg    120tacctgcaga agcccggcca gagcccccag ctgctgatct acaaggtgag caaccgcttc    180agcggcgtgc ccgaccgctt cagcggcagc ggcagcggca ccgacttcac cctgaagatc    240agccgcgtgg aggccgagga cgtgggcgtg tactactgca gccagaacac ccacgtgccc    300cccaccttcg gccagggcac caagctggag atcaagggtg gcggtggctc gggaggtgga    360gggtcgggtg gcggcggatc tcaggtgcag ctggtgcaga gcggcgccga ggtgaagaag    420cccggcgcca gcgtgaaggt gagctgcaag gccagcggct acaccttcac cgactacgag    480atgcactggg tgcgccaggc ccccggccag ggcctggagt ggatgggcgc cctggacccc    540aagaccggcg acaccgccta cagccagaag ttcaagggcc gcgtgaccct gaccgccgac    600aagagcacca gcaccgccta catggagctg agcagcctga ccagcgagga caccgccgtg    660tactactgca cccgcttcta cagctacacc tactggggcc agggcaccct ggtgaccgtg    720agcagc                                                               726</s400><s200><s210>24</s210><s211>242</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 24Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly1               5                   10                  15Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser            20                  25                  30Asn Arg Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser        35                  40                  45Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro    50                  55                  60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65                  70                  75                  80Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Asn                85                  90                  95Thr His Val Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys            100                 105                 110Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln        115                 120                 125Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser    130                 135                 140Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Glu145                 150                 155                 160Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly                165                 170                 175Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe Lys            180                 185                 190Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met        195                 200                 205Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr    210                 215                 220Arg Phe Tyr Ser Tyr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr Val225                 230                 235                 240Ser Ser</s400><s200><s210>25</s210><s211>705</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 25caggtgcagc tggtggagag tggaggtggc gtggtacagc ccggccgcag cctgcgcctg     60gactgcaagg ccagcggcat caccttcagc aacagcggca tgcactgggt gcgccaggcc    120cccggcaagg gcctggagtg ggtggccgtg atctggtacg acggcagcaa gcgctactac    180gccgacagcg tgaagggccg cttcaccatc agccgcgaca acagcaagaa caccctgttc    240ctgcagatga acagcctgcg cgccgaggac accgccgtgt actactgcgc caccaacgac    300gactactggg gccagggcac cctggtgacc gtgagcagcg gtggcggtgg ctcgggcggt    360ggtgggtcgg gtggcggcgg atctgagatc gtgctgaccc agagccccgc caccctgagc    420ctgagccccg gcgagcgcgc caccctgagc tgccgcgcca gccagagcgt gagcagctac    480ctggcctggt accagcagaa gccaggacag gctccacgac tgctaatcta tgacgccagc    540aaccgcgcca ccggcatccc cgcccgcttc agcggcagcg gcagcggcac cgacttcacc    600ctgaccatca gcagcctgga gcccgaggac ttcgccgtgt actactgcca gcagagcagc    660aactggcccc gcaccttcgg ccagggcacc aaggtggaga tcaag                    705</s400><s200><s210>26</s210><s211>235</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 26Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Asp Cys Lys Ala Ser Gly Ile Thr Phe Ser Asn Ser            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Val Ile Trp Tyr Asp Gly Ser Lys Arg Tyr Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Thr Asn Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser            100                 105                 110Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser        115                 120                 125Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly    130                 135                 140Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr145                 150                 155                 160Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile                165                 170                 175Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly            180                 185                 190Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro        195                 200                 205Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Ser Asn Trp Pro Arg    210                 215                 220Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys225                 230                 235</s400><s200><s210>27</s210><s211>720</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 27gaggtgcagc tggtggagag cggaggtgga ctagtacagc ctggtggcag cctacgactg     60agttgcgccg ccagcggctt caccttcagc gacagctgga tccactgggt gcgccaggcc    120cccggcaagg gcctggagtg ggtggcctgg atcagcccct acggcggcag cacctactac    180gccgacagcg tgaagggccg cttcaccatc agcgccgaca ccagcaagaa caccgcctac    240ctgcagatga acagcctgcg cgccgaggac accgccgtgt actactgcgc ccgccgccac    300tggcccggcg gcttcgacta ctggggccag ggcaccctgg tgaccgtgag cagcggaggc    360gggggaagcg gcggcggagg gtctggagga gggggcagtg acatccagat gacccagagc    420cccagcagcc tgagcgccag cgtgggcgac cgcgtgacca tcacctgccg cgccagccag    480gacgtgagca ccgccgtggc ctggtaccag cagaagcccg gcaaggcccc caagctgctg    540atctacagcg ccagcttcct gtacagcggc gtgcccagcc gcttcagcgg cagcggcagc    600ggcaccgact tcaccctgac catcagcagc ctgcagcccg aggacttcgc cacctactac    660tgccagcagt acctgtacca ccccgccacc ttcggccagg gcaccaaggt ggagatcaag    720</s400><s200><s210>28</s210><s211>240</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 28Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ser            20                  25                  30Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Arg His Trp Pro Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr            100                 105                 110Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser        115                 120                 125Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu    130                 135                 140Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln145                 150                 155                 160Asp Val Ser Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala                165                 170                 175Pro Lys Leu Leu Ile Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro            180                 185                 190Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile        195                 200                 205Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr    210                 215                 220Leu Tyr His Pro Ala Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys225                 230                 235                 240</s400><s200><s210>29</s210><s211>57</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 29gccaccaact tcagcctgct gaagcaggcc ggcgacgtgg aggagaaccc cggcccc        57</s400><s200><s210>30</s210><s211>19</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 30Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp Val Glu Glu Asn1               5                   10                  15Pro Gly Pro</s400><s200><s210>31</s210><s211>711</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 31gacatccaga tgacccagag ccccagcagc ctgagcacca gcgtgggcga ccgcgtgacc     60ctgacctgca aggccagcca ggacgtgggc accgccgtgg actggtacca gcagaagccc    120ggccccagcc ccaagctgct gatctactgg gccagcaccc gccacaccgg catccccagc    180cgcttcagcg gcagcggcag cggcaccgac ttcaccctga ccatcagcag cctgcagccc    240gaggacttcg ccgactacta ctgccagcag tacaacagct accccctgac cttcggcccc    300ggcaccaagg tggacatcaa gggtggcggt ggctcgggcg gtggtgggtc gggtggcggc    360ggatctgagg tgcagctggt gcagagcggc cccgaggtga agaagcccgg cgccaccgtg    420aagatcagct gcaagaccag cggctacacc ttcaccgagt acaccatcca ctgggtgaag    480caggcccccg gcaagggcct ggagtggatc ggcaacatca accccaacaa cggcggcacc    540acctacaacc agaagttcga ggacaaggcc accctgaccg tggacaagag caccgacacc    600gcctacatgg agctgagcag cctgcgcagc gaggacaccg ccgtgtacta ctgcgccgcc    660ggctggaact tcgactactg gggccagggc accctactta cagtaagtag c             711</s400><s200><s210>32</s210><s211>1044</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 32gacatccaga tgacccagag ccccagcagc ctgagcacca gcgtgggcga ccgcgtgacc     60ctgacctgca aggccagcca ggacgtgggc accgccgtgg actggtacca gcagaagccc    120ggccagagcc ccaagctgct gatctactgg gccagcaccc gccacaccgg catccccagc    180cgcttcagcg gcagcggcag cggcaccgac ttcaccctga ccatcagcag cctgcagccc    240gaggacttcg ccgactacta ctgccagcag tacaacagct accccctgac cttcggcccc    300ggcaccaagg tggacatcaa gggtggcggt ggctcgggcg gtggtgggtc gggtggcggc    360ggatctgagg tgcagctggt gcagagcggc cccgaggtga agaagcccgg cgccaccgtg    420aagatcagct gcaagaccag cggctacacc ttcaccgagt acaccatcca ctgggtgaag    480caggcccccg gcaagggcct ggagtggatc ggcaacatca accccaacaa cggcggcacc    540acctacaacc agaagttcga ggacaaggcc accctgaccg tggacaagag caccgacacc    600gcctacatgg agctgagcag cctgcgcagc gaggacaccg ccgtgtacta ctgcgccgcc    660ggctggaact tcgactactg gggccagggc accctactta cagtaagtag caccacgacg    720ccagcgccgc gaccaccaac accggcgccc accatcgcgt cgcagcccct gtccctgcgc    780ccagaggcgt gccggccagc ggcggggggc gcagtgcaca cgagggggct ggacttcgcc    840tgtgatatct acatctgggc gcccttggcc gggacttgtg gggtccttct cctgtcactg    900gttatcaccc tttactgcaa acggggcaga aagaaactcc tgtatatatt caaacaacca    960tttatgagac cagtacaaac tactcaagag gaagatggct gtagctgccg atttccagaa   1020gaagaagaag gaggatgtga actg                                          1044</s400><s200><s210>33</s210><s211>1380</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 33gacatccaga tgacccagag ccccagcagc ctgagcacca gcgtgggcga ccgcgtgacc     60ctgacctgca aggccagcca ggacgtgggc accgccgtgg actggtacca gcagaagccc    120ggccagagcc ccaagctgct gatctactgg gccagcaccc gccacaccgg catccccagc    180cgcttcagcg gcagcggcag cggcaccgac ttcaccctga ccatcagcag cctgcagccc    240gaggacttcg ccgactacta ctgccagcag tacaacagct accccctgac cttcggcccc    300ggcaccaagg tggacatcaa gggtggcggt ggctcgggcg gtggtgggtc gggtggcggc    360ggatctgagg tgcagctggt gcagagcggc cccgaggtga agaagcccgg cgccaccgtg    420aagatcagct gcaagaccag cggctacacc ttcaccgagt acaccatcca ctgggtgaag    480caggcccccg gcaagggcct ggagtggatc ggcaacatca accccaacaa cggcggcacc    540acctacaacc agaagttcga ggacaaggcc accctgaccg tggacaagag caccgacacc    600gcctacatgg agctgagcag cctgcgcagc gaggacaccg ccgtgtacta ctgcgccgcc    660ggctggaact tcgactactg gggccagggc accctactta cagtaagtag caccacgacg    720ccagcgccgc gaccaccaac accggcgccc accatcgcgt cgcagcccct gtccctgcgc    780ccagaggcgt gccggccagc ggcggggggc gcagtgcaca cgagggggct ggacttcgcc    840tgtgatatct acatctgggc gcccttggcc gggacttgtg gggtccttct cctgtcactg    900gttatcaccc tttactgcaa acggggcaga aagaaactcc tgtatatatt caaacaacca    960tttatgagac cagtacaaac tactcaagag gaagatggct gtagctgccg atttccagaa   1020gaagaagaag gaggatgtga actgagagtg aagttcagca ggagcgcaga cgcccccgcg   1080tacaagcagg gccagaacca gctctataac gagctcaatc taggacgaag agaggagtac   1140gatgttttgg acaagagacg tggccgggac cctgagatgg ggggaaagcc gagaaggaag   1200aaccctcagg aaggcctgta caatgaactg cagaaagata agatggcgga ggcctacagt   1260gagattggga tgaaaggcga gcgccggagg ggcaaggggc acgatggcct ttaccagggt   1320ctcagtacag ccaccaagga cacctacgac gcccttcaca tgcaggccct gccccctcgc   1380</s400><s200><s210>34</s210><s211>3264</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 34gacatccaga tgacccagag ccccagcagc ctgagcacca gcgtgggcga ccgcgtgacc     60ctgacctgca aggccagcca ggacgtgggc accgccgtgg actggtacca gcagaagccc    120ggccagagcc ccaagctgct gatctactgg gccagcaccc gccacaccgg catccccagc    180cgcttcagcg gcagcggcag cggcaccgac ttcaccctga ccatcagcag cctgcagccc    240gaggacttcg ccgactacta ctgccagcag tacaacagct accccctgac cttcggcccc    300ggcaccaagg tggacatcaa gggtggcggt ggctcgggcg gtggtgggtc gggtggcggc    360ggatctgagg tgcagctggt gcagagcggc cccgaggtga agaagcccgg cgccaccgtg    420aagatcagct gcaagaccag cggctacacc ttcaccgagt acaccatcca ctgggtgaag    480caggcccccg gcaagggcct ggagtggatc ggcaacatca accccaacaa cggcggcacc    540acctacaacc agaagttcga ggacaaggcc accctgaccg tggacaagag caccgacacc    600gcctacatgg agctgagcag cctgcgcagc gaggacaccg ccgtgtacta ctgcgccgcc    660ggctggaact tcgactactg gggccagggc accctactta cagtaagtag caccacgacg    720ccagcgccgc gaccaccaac accggcgccc accatcgcgt cgcagcccct gtccctgcgc    780ccagaggcgt gccggccagc ggcggggggc gcagtgcaca cgagggggct ggacttcgcc    840tgtgatatct acatctgggc gcccttggcc gggacttgtg gggtccttct cctgtcactg    900gttatcaccc tttactgcaa acggggcaga aagaaactcc tgtatatatt caaacaacca    960tttatgagac cagtacaaac tactcaagag gaagatggct gtagctgccg atttccagaa   1020gaagaagaag gaggatgtga actgtaagct agccgactgt gccttctagt tgccagccat   1080ctgttgtttg cccctccccc gtgccttcct tgaccctgga aggtgccact cccactgtcc   1140tttcctaata aaatgaggaa attgcatcgc attgtctgag taggtgtcat tctattctgg   1200ggggtggggt ggggcaggac agcaaggggg aggattggga agacaatagc aggcatgctg   1260gggatgcggt gggctctatg gcatatgggt atcgataagc ttgatatcga attaggagga   1320aaaactgttt catacagaag gcgtcaatta ggaggaaaaa ctgtttcata cagaaggcgt   1380caattaggag gaaaaactgt ttcatacaga aggcgtcaat tggtcccatc gaattaggag   1440gaaaaactgt ttcatacaga aggcgtcaat taggaggaaa aactgtttca tacagaaggc   1500gtcaattagg aggaaaaact gtttcataca gaaggcgtca attggtcccg ggacattttg   1560acacccccat aatatttttc cagaattaac agtataaatt gcatctcttg ttcaagagtt   1620ccctatcact ctctttaatc actactcaca gtaacctcaa ctcctgtcta gaccaccatg   1680gagtttgggc tgagctgggt tttcctcgtt gctcttttta gaggtgtaca gtgtatctgg   1740gagctgaaga aggacgtgta cgtggtggag ctggactggt accccgacgc ccccggcgag   1800atggtggtat taacctgcga caccccagag gaagacggca tcacctggac cctggaccag   1860tcaagcgagg tgctgggtag cggcaagacc ctgaccatcc aggtgaagga gttcggcgac   1920gccggccagt acacctgcca caagggcggc gaggtgctga gccacagcct actgcttctc   1980cacaagaagg aggacggcat ctggagcacc gacatcctga aggaccagaa ggagcccaag   2040aacaagacct tcctgcgctg cgaggccaag aattactcag gacgattcac ctgctggtgg   2100ctgaccacca tcagcaccga cctgaccttc agcgtgaaga gcagccgcgg cagcagcgac   2160ccccagggcg tgacctgcgg cgccgccacc ctgagcgccg agcgcgtgcg cggcgacaac   2220aaggagtacg agtacagcgt ggagtgccag gaggacagcg cctgccccgc cgccgaggag   2280agcctgccca tcgaggtgat ggtggacgcc gtgcacaagc tgaagtacga gaactacacc   2340agcagcttct tcatccgcga catcatcaag cccgaccccc ccaagaacct gcagctgaag   2400cccctgaaga acagccgcca ggtggaggtg agctgggagt accccgacac ctggagcacc   2460ccccacagct acttcagcct gaccttctgc gtgcaggtgc agggcaagag caagcgcgag   2520aagaaggacc gcgtgttcac cgacaagacc agcgccaccg tgatctgccg caagaatgcg   2580agcatcagcg tgcgcgccca ggaccgctac tacagcagca gctggagcga gtgggccagc   2640gtgccctgca gcggaggtgg cggtggaggc agccgcaacc tgcccgtggc cacccccgac   2700cccggcatgt tcccctgcct gcaccacagc cagaacctgc tgcgcgccgt gagcaacatg   2760ctgcagaagg cccgccagac cctggagttc tacccctgca ccagcgagga gatcgaccac   2820gaggacatca ccaaggacaa gaccagcacc gtggaggcct gcctgcccct ggagctgacc   2880aagaacgaga gctgtctgaa cagcagagag actagcttca tcactaacgg cagctgccta   2940gccagccgca agaccagctt catgatggcc ctgtgcctga gcagcatcta cgaggacctg   3000aagatgtacc aggtggagtt caagaccatg aacgccaagc tgctgatgga ccccaagcgc   3060cagatcttcc tggaccagaa catgctggcc gtgatcgacg agctgatgca ggccctgaac   3120ttcaacagcg agaccgtgcc ccagaagagc agcctggagg agcccgactt ctacaagacc   3180aagatcaagc tgtgcatcct gctgcacgcc ttccgcatcc gcgccgtgac catcgaccgc   3240gtgatgagct acctgaacgc atca                                          3264</s400><s200><s210>35</s210><s211>3600</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 35gacatccaga tgacccagag ccccagcagc ctgagcacca gcgtgggcga ccgcgtgacc     60ctgacctgca aggccagcca ggacgtgggc accgccgtgg actggtacca gcagaagccc    120ggccagagcc ccaagctgct gatctactgg gccagcaccc gccacaccgg catccccagc    180cgcttcagcg gcagcggcag cggcaccgac ttcaccctga ccatcagcag cctgcagccc    240gaggacttcg ccgactacta ctgccagcag tacaacagct accccctgac cttcggcccc    300ggcaccaagg tggacatcaa gggtggcggt ggctcgggcg gtggtgggtc gggtggcggc    360ggatctgagg tgcagctggt gcagagcggc cccgaggtga agaagcccgg cgccaccgtg    420aagatcagct gcaagaccag cggctacacc ttcaccgagt acaccatcca ctgggtgaag    480caggcccccg gcaagggcct ggagtggatc ggcaacatca accccaacaa cggcggcacc    540acctacaacc agaagttcga ggacaaggcc accctgaccg tggacaagag caccgacacc    600gcctacatgg agctgagcag cctgcgcagc gaggacaccg ccgtgtacta ctgcgccgcc    660ggctggaact tcgactactg gggccagggc accctactta cagtaagtag caccacgacg    720ccagcgccgc gaccaccaac accggcgccc accatcgcgt cgcagcccct gtccctgcgc    780ccagaggcgt gccggccagc ggcggggggc gcagtgcaca cgagggggct ggacttcgcc    840tgtgatatct acatctgggc gcccttggcc gggacttgtg gggtccttct cctgtcactg    900gttatcaccc tttactgcaa acggggcaga aagaaactcc tgtatatatt caaacaacca    960tttatgagac cagtacaaac tactcaagag gaagatggct gtagctgccg atttccagaa   1020gaagaagaag gaggatgtga actgagagtg aagttcagca ggagcgcaga cgcccccgcg   1080tacaagcagg gccagaacca gctctataac gagctcaatc taggacgaag agaggagtac   1140gatgttttgg acaagagacg tggccgggac cctgagatgg ggggaaagcc gagaaggaag   1200aaccctcagg aaggcctgta caatgaactg cagaaagata agatggcgga ggcctacagt   1260gagattggga tgaaaggcga gcgccggagg ggcaaggggc acgatggcct ttaccagggt   1320ctcagtacag ccaccaagga cacctacgac gcccttcaca tgcaggccct gccccctcgc   1380taagctagcc gactgtgcct tctagttgcc agccatctgt tgtttgcccc tcccccgtgc   1440cttccttgac cctggaaggt gccactccca ctgtcctttc ctaataaaat gaggaaattg   1500catcgcattg tctgagtagg tgtcattcta ttctgggggg tggggtgggg caggacagca   1560agggggagga ttgggaagac aatagcaggc atgctgggga tgcggtgggc tctatggcat   1620atgggtatcg ataagcttga tatcgaatta ggaggaaaaa ctgtttcata cagaaggcgt   1680caattaggag gaaaaactgt ttcatacaga aggcgtcaat taggaggaaa aactgtttca   1740tacagaaggc gtcaattggt cccatcgaat taggaggaaa aactgtttca tacagaaggc   1800gtcaattagg aggaaaaact gtttcataca gaaggcgtca attaggagga aaaactgttt   1860catacagaag gcgtcaattg gtcccgggac attttgacac ccccataata tttttccaga   1920attaacagta taaattgcat ctcttgttca agagttccct atcactctct ttaatcacta   1980ctcacagtaa cctcaactcc tgtctagacc accatggagt ttgggctgag ctgggttttc   2040ctcgttgctc tttttagagg tgtacagtgt atctgggagc tgaagaagga cgtgtacgtg   2100gtggagctgg actggtaccc cgacgccccc ggcgagatgg tggtattaac ctgcgacacc   2160ccagaggaag acggcatcac ctggaccctg gaccagtcaa gcgaggtgct gggtagcggc   2220aagaccctga ccatccaggt gaaggagttc ggcgacgccg gccagtacac ctgccacaag   2280ggcggcgagg tgctgagcca cagcctactg cttctccaca agaaggagga cggcatctgg   2340agcaccgaca tcctgaagga ccagaaggag cccaagaaca agaccttcct gcgctgcgag   2400gccaagaatt actcaggacg attcacctgc tggtggctga ccaccatcag caccgacctg   2460accttcagcg tgaagagcag ccgcggcagc agcgaccccc agggcgtgac ctgcggcgcc   2520gccaccctga gcgccgagcg cgtgcgcggc gacaacaagg agtacgagta cagcgtggag   2580tgccaggagg acagcgcctg ccccgccgcc gaggagagcc tgcccatcga ggtgatggtg   2640gacgccgtgc acaagctgaa gtacgagaac tacaccagca gcttcttcat ccgcgacatc   2700atcaagcccg acccccccaa gaacctgcag ctgaagcccc tgaagaacag ccgccaggtg   2760gaggtgagct gggagtaccc cgacacctgg agcacccccc acagctactt cagcctgacc   2820ttctgcgtgc aggtgcaggg caagagcaag cgcgagaaga aggaccgcgt gttcaccgac   2880aagaccagcg ccaccgtgat ctgccgcaag aatgcgagca tcagcgtgcg cgcccaggac   2940cgctactaca gcagcagctg gagcgagtgg gccagcgtgc cctgcagcgg aggtggcggt   3000ggaggcagcc gcaacctgcc cgtggccacc cccgaccccg gcatgttccc ctgcctgcac   3060cacagccaga acctgctgcg cgccgtgagc aacatgctgc agaaggcccg ccagaccctg   3120gagttctacc cctgcaccag cgaggagatc gaccacgagg acatcaccaa ggacaagacc   3180agcaccgtgg aggcctgcct gcccctggag ctgaccaaga acgagagctg tctgaacagc   3240agagagacta gcttcatcac taacggcagc tgcctagcca gccgcaagac cagcttcatg   3300atggccctgt gcctgagcag catctacgag gacctgaaga tgtaccaggt ggagttcaag   3360accatgaacg ccaagctgct gatggacccc aagcgccaga tcttcctgga ccagaacatg   3420ctggccgtga tcgacgagct gatgcaggcc ctgaacttca acagcgagac cgtgccccag   3480aagagcagcc tggaggagcc cgacttctac aagaccaaga tcaagctgtg catcctgctg   3540cacgccttcc gcatccgcgc cgtgaccatc gaccgcgtga tgagctacct gaacgcatca   3600</s400><s200><s210>36</s210><s211>2076</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 36gacatccaga tgacccagag ccccagcagc ctgagcacca gcgtgggcga ccgcgtgacc     60ctgacctgca aggccagcca ggacgtgggc accgccgtgg actggtacca gcagaagccc    120ggccagagcc ccaagctgct gatctactgg gccagcaccc gccacaccgg catccccagc    180cgcttcagcg gcagcggcag cggcaccgac ttcaccctga ccatcagcag cctgcagccc    240gaggacttcg ccgactacta ctgccagcag tacaacagct accccctgac cttcggcccc    300ggcaccaagg tggacatcaa gggtggcggt ggctcgggcg gtggtgggtc gggtggcggc    360ggatctgagg tgcagctggt gcagagcggc cccgaggtga agaagcccgg cgccaccgtg    420aagatcagct gcaagaccag cggctacacc ttcaccgagt acaccatcca ctgggtgaag    480caggcccccg gcaagggcct ggagtggatc ggcaacatca accccaacaa cggcggcacc    540acctacaacc agaagttcga ggacaaggcc accctgaccg tggacaagag caccgacacc    600gcctacatgg agctgagcag cctgcgcagc gaggacaccg ccgtgtacta ctgcgccgcc    660ggctggaact tcgactactg gggccagggc accctactta cagtaagtag caccacgacg    720ccagcgccgc gaccaccaac accggcgccc accatcgcgt cgcagcccct gtccctgcgc    780ccagaggcgt gccggccagc ggcggggggc gcagtgcaca cgagggggct ggacttcgcc    840tgtgatatct acatctgggc gcccttggcc gggacttgtg gggtccttct cctgtcactg    900gttatcaccc tttactgcaa acggggcaga aagaaactcc tgtatatatt caaacaacca    960tttatgagac cagtacaaac tactcaagag gaagatggct gtagctgccg atttccagaa   1020gaagaagaag gaggatgtga actgtaagct agccgactgt gccttctagt tgccagccat   1080ctgttgtttg cccctccccc gtgccttcct tgaccctgga aggtgccact cccactgtcc   1140tttcctaata aaatgaggaa attgcatcgc attgtctgag taggtgtcat tctattctgg   1200ggggtggggt ggggcaggac agcaaggggg aggattggga agacaatagc aggcatgctg   1260gggatgcggt gggctctatg gcatatgggt atcgataagc ttgatatcga attaggagga   1320aaaactgttt catacagaag gcgtcaatta ggaggaaaaa ctgtttcata cagaaggcgt   1380caattaggag gaaaaactgt ttcatacaga aggcgtcaat tggtcccatc gaattaggag   1440gaaaaactgt ttcatacaga aggcgtcaat taggaggaaa aactgtttca tacagaaggc   1500gtcaattagg aggaaaaact gtttcataca gaaggcgtca attggtcccg ggacattttg   1560acacccccat aatatttttc cagaattaac agtataaatt gcatctcttg ttcaagagtt   1620ccctatcact ctctttaatc actactcaca gtaacctcaa ctcctgtcta gaccaccatg   1680gagtttgggc tgagctgggt tttcctcgtt gctcttttta gaggtgtaca gtgtaactgg   1740gtgaacgtga tcagcgacct gaagaagatc gaggacctga tccagagcat gcacatcgac   1800gccaccctgt acaccgagag cgacgtgcac cccagctgca aggtgaccgc catgaagtgc   1860ttcctgctgg agctgcaggt gatcagcctg gagagcggcg acgccagcat ccacgacacc   1920gtggagaacc tgatcatcct ggccaacaac agcctgagca gcaacggcaa cgtgaccgag   1980agcggctgca aggagtgcga ggagctggag gagaagaaca tcaaggagtt cctgcagagc   2040ttcgtgcaca tcgtgcagat gttcatcaac accagc                             2076</s400><s200><s210>37</s210><s211>2412</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 37gacatccaga tgacccagag ccccagcagc ctgagcacca gcgtgggcga ccgcgtgacc     60ctgacctgca aggccagcca ggacgtgggc accgccgtgg actggtacca gcagaagccc    120ggccagagcc ccaagctgct gatctactgg gccagcaccc gccacaccgg catccccagc    180cgcttcagcg gcagcggcag cggcaccgac ttcaccctga ccatcagcag cctgcagccc    240gaggacttcg ccgactacta ctgccagcag tacaacagct accccctgac cttcggcccc    300ggcaccaagg tggacatcaa gggtggcggt ggctcgggcg gtggtgggtc gggtggcggc    360ggatctgagg tgcagctggt gcagagcggc cccgaggtga agaagcccgg cgccaccgtg    420aagatcagct gcaagaccag cggctacacc ttcaccgagt acaccatcca ctgggtgaag    480caggcccccg gcaagggcct ggagtggatc ggcaacatca accccaacaa cggcggcacc    540acctacaacc agaagttcga ggacaaggcc accctgaccg tggacaagag caccgacacc    600gcctacatgg agctgagcag cctgcgcagc gaggacaccg ccgtgtacta ctgcgccgcc    660ggctggaact tcgactactg gggccagggc accctactta cagtaagtag caccacgacg    720ccagcgccgc gaccaccaac accggcgccc accatcgcgt cgcagcccct gtccctgcgc    780ccagaggcgt gccggccagc ggcggggggc gcagtgcaca cgagggggct ggacttcgcc    840tgtgatatct acatctgggc gcccttggcc gggacttgtg gggtccttct cctgtcactg    900gttatcaccc tttactgcaa acggggcaga aagaaactcc tgtatatatt caaacaacca    960tttatgagac cagtacaaac tactcaagag gaagatggct gtagctgccg atttccagaa   1020gaagaagaag gaggatgtga actgagagtg aagttcagca ggagcgcaga cgcccccgcg   1080tacaagcagg gccagaacca gctctataac gagctcaatc taggacgaag agaggagtac   1140gatgttttgg acaagagacg tggccgggac cctgagatgg ggggaaagcc gagaaggaag   1200aaccctcagg aaggcctgta caatgaactg cagaaagata agatggcgga ggcctacagt   1260gagattggga tgaaaggcga gcgccggagg ggcaaggggc acgatggcct ttaccagggt   1320ctcagtacag ccaccaagga cacctacgac gcccttcaca tgcaggccct gccccctcgc   1380taagctagcc gactgtgcct tctagttgcc agccatctgt tgtttgcccc tcccccgtgc   1440cttccttgac cctggaaggt gccactccca ctgtcctttc ctaataaaat gaggaaattg   1500catcgcattg tctgagtagg tgtcattcta ttctgggggg tggggtgggg caggacagca   1560agggggagga ttgggaagac aatagcaggc atgctgggga tgcggtgggc tctatggcat   1620atgggtatcg ataagcttga tatcgaatta ggaggaaaaa ctgtttcata cagaaggcgt   1680caattaggag gaaaaactgt ttcatacaga aggcgtcaat taggaggaaa aactgtttca   1740tacagaaggc gtcaattggt cccatcgaat taggaggaaa aactgtttca tacagaaggc   1800gtcaattagg aggaaaaact gtttcataca gaaggcgtca attaggagga aaaactgttt   1860catacagaag gcgtcaattg gtcccgggac attttgacac ccccataata tttttccaga   1920attaacagta taaattgcat ctcttgttca agagttccct atcactctct ttaatcacta   1980ctcacagtaa cctcaactcc tgtctagacc accatggagt ttgggctgag ctgggttttc   2040ctcgttgctc tttttagagg tgtacagtgt aactgggtga acgtgatcag cgacctgaag   2100aagatcgagg acctgatcca gagcatgcac atcgacgcca ccctgtacac cgagagcgac   2160gtgcacccca gctgcaaggt gaccgccatg aagtgcttcc tgctggagct gcaggtgatc   2220agcctggaga gcggcgacgc cagcatccac gacaccgtgg agaacctgat catcctggcc   2280aacaacagcc tgagcagcaa cggcaacgtg accgagagcg gctgcaagga gtgcgaggag   2340ctggaggaga agaacatcaa ggagttcctg cagagcttcg tgcacatcgt gcagatgttc   2400atcaacacca gc                                                       2412</s400><s200><s210>38</s210><s211>2205</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 38gacatccaga tgacccagag ccccagcagc ctgagcacca gcgtgggcga ccgcgtgacc     60ctgacctgca aggccagcca ggacgtgggc accgccgtgg actggtacca gcagaagccc    120ggccccagcc ccaagctgct gatctactgg gccagcaccc gccacaccgg catccccagc    180cgcttcagcg gcagcggcag cggcaccgac ttcaccctga ccatcagcag cctgcagccc    240gaggacttcg ccgactacta ctgccagcag tacaacagct accccctgac cttcggcccc    300ggcaccaagg tggacatcaa gggtggcggt ggctcgggcg gtggtgggtc gggtggcggc    360ggatctgagg tgcagctggt gcagagcggc cccgaggtga agaagcccgg cgccaccgtg    420aagatcagct gcaagaccag cggctacacc ttcaccgagt acaccatcca ctgggtgaag    480caggcccccg gcaagggcct ggagtggatc ggcaacatca accccaacaa cggcggcacc    540acctacaacc agaagttcga ggacaaggcc accctgaccg tggacaagag caccgacacc    600gcctacatgg agctgagcag cctgcgcagc gaggacaccg ccgtgtacta ctgcgccgcc    660ggctggaact tcgactactg gggccagggc accctactta cagtaagtag caccacgacg    720ccagcgccgc gaccaccaac accggcgccc accatcgcgt cgcagcccct gtccctgcgc    780ccagaggcgt gccggccagc ggcggggggc gcagtgcaca cgagggggct ggacttcgcc    840tgtgatatct acatctgggc gcccttggcc gggacttgtg gggtccttct cctgtcactg    900gttatcaccc tttactgcaa acggggcaga aagaaactcc tgtatatatt caaacaacca    960tttatgagac cagtacaaac tactcaagag gaagatggct gtagctgccg atttccagaa   1020gaagaagaag gaggatgtga actgtaagct agccgactgt gccttctagt tgccagccat   1080ctgttgtttg cccctccccc gtgccttcct tgaccctgga aggtgccact cccactgtcc   1140tttcctaata aaatgaggaa attgcatcgc attgtctgag taggtgtcat tctattctgg   1200ggggtggggt ggggcaggac agcaaggggg aggattggga agacaatagc aggcatgctg   1260gggatgcggt gggctctatg gcatatgggt atcgataagc ttgatatcga attaggagga   1320aaaactgttt catacagaag gcgtcaatta ggaggaaaaa ctgtttcata cagaaggcgt   1380caattaggag gaaaaactgt ttcatacaga aggcgtcaat tggtcccatc gaattaggag   1440gaaaaactgt ttcatacaga aggcgtcaat taggaggaaa aactgtttca tacagaaggc   1500gtcaattagg aggaaaaact gtttcataca gaaggcgtca attggtcccg ggacattttg   1560acacccccat aatatttttc cagaattaac agtataaatt gcatctcttg ttcaagagtt   1620ccctatcact ctctttaatc actactcaca gtaacctcaa ctcctgtcta gaccaccatg   1680gagtttgggc tgagctgggt tttcctcgtt gctcttttta gaggtgtaca gtgttacttc   1740ggcaagctgg agagcaagct gagcgtgatc cgcaacctga acgaccaggt gctgttcatc   1800gaccagggca accgccccct gttcgaggac atgaccgaca gcgactgccg cgacaacgcc   1860ccccgcacca tcttcatcat cagcatgtac aaggacagcc agccccgcgg catggccgtg   1920accatcagcg tgaagtgcga gaagatcagc accctgagct gcgagaacaa gatcatcagc   1980ttcaaggaga tgaacccccc cgacaacatc aaggacacca agagcgacat catcttcttc   2040cagcgcagcg tgcccggcca cgacaacaag atgcagttcg agagcagcag ctacgagggc   2100tacttcctgg cctgcgagaa ggagcgcgac ctgttcaagc tgatcctgaa gaaggaggac   2160gagctgggcg accgcagcat catgttcacc gtgcagaacg aggac                   2205</s400><s200><s210>39</s210><s211>2133</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 39gacatccaga tgacccagag ccccagcagc ctgagcacca gcgtgggcga ccgcgtgacc     60ctgacctgca aggccagcca ggacgtgggc accgccgtgg actggtacca gcagaagccc    120ggccccagcc ccaagctgct gatctactgg gccagcaccc gccacaccgg catccccagc    180cgcttcagcg gcagcggcag cggcaccgac ttcaccctga ccatcagcag cctgcagccc    240gaggacttcg ccgactacta ctgccagcag tacaacagct accccctgac cttcggcccc    300ggcaccaagg tggacatcaa gggtggcggt ggctcgggcg gtggtgggtc gggtggcggc    360ggatctgagg tgcagctggt gcagagcggc cccgaggtga agaagcccgg cgccaccgtg    420aagatcagct gcaagaccag cggctacacc ttcaccgagt acaccatcca ctgggtgaag    480caggcccccg gcaagggcct ggagtggatc ggcaacatca accccaacaa cggcggcacc    540acctacaacc agaagttcga ggacaaggcc accctgaccg tggacaagag caccgacacc    600gcctacatgg agctgagcag cctgcgcagc gaggacaccg ccgtgtacta ctgcgccgcc    660ggctggaact tcgactactg gggccagggc accctactta cagtaagtag caccacgacg    720ccagcgccgc gaccaccaac accggcgccc accatcgcgt cgcagcccct gtccctgcgc    780ccagaggcgt gccggccagc ggcggggggc gcagtgcaca cgagggggct ggacttcgcc    840tgtgatatct acatctgggc gcccttggcc gggacttgtg gggtccttct cctgtcactg    900gttatcaccc tttactgcaa acggggcaga aagaaactcc tgtatatatt caaacaacca    960tttatgagac cagtacaaac tactcaagag gaagatggct gtagctgccg atttccagaa   1020gaagaagaag gaggatgtga actgtaagct agccgactgt gccttctagt tgccagccat   1080ctgttgtttg cccctccccc gtgccttcct tgaccctgga aggtgccact cccactgtcc   1140tttcctaata aaatgaggaa attgcatcgc attgtctgag taggtgtcat tctattctgg   1200ggggtggggt ggggcaggac agcaaggggg aggattggga agacaatagc aggcatgctg   1260gggatgcggt gggctctatg gcatatgggt atcgataagc ttgatatcga attaggagga   1320aaaactgttt catacagaag gcgtcaatta ggaggaaaaa ctgtttcata cagaaggcgt   1380caattaggag gaaaaactgt ttcatacaga aggcgtcaat tggtcccatc gaattaggag   1440gaaaaactgt ttcatacaga aggcgtcaat taggaggaaa aactgtttca tacagaaggc   1500gtcaattagg aggaaaaact gtttcataca gaaggcgtca attggtcccg ggacattttg   1560acacccccat aatatttttc cagaattaac agtataaatt gcatctcttg ttcaagagtt   1620ccctatcact ctctttaatc actactcaca gtaacctcaa ctcctgtcta gaccaccatg   1680gagtttgggc tgagctgggt tttcctcgtt gctcttttta gaggtgtaca gtgtgcccca   1740accagctcaa gtactaagaa gacacagctg cagctggagc acctgctgct ggacctgcag   1800atgatcctga acggcatcaa caactacaag aaccccaagc tgacccgcat gctgaccttc   1860aagttctaca tgcccaagaa ggccaccgag ctgaagcacc tgcagtgcct ggaggaggag   1920ctgaagcccc tggaggaggt gctgaacctg gcccagagca agaacttcca cctgcgcccc   1980cgcgacctga tcagcaacat caacgtgatc gtgctggagc tgaagggcag cgagaccacc   2040ttcatgtgcg agtacgccga cgagaccgcc accatcgtgg agttcctgaa ccgctggatc   2100accttctgcc agagcatcat cagcaccctg acc                                2133</s400><s200><s210>40</s210><s211>3392</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 40gacatccaga tgacccagag ccccagcagc ctgagcacca gcgtgggcga ccgcgtgacc     60ctgacctgca aggccagcca ggacgtgggc accgccgtgg actggtacca gcagaagccc    120ggccagagcc ccaagctgct gatctactgg gccagcaccc gccacaccgg catccccagc    180cgcttcagcg gcagcggcag cggcaccgac ttcaccctga ccatcagcag cctgcagccc    240gaggacttcg ccgactacta ctgccagcag tacaacagct accccctgac cttcggcccc    300ggcaccaagg tggacatcaa gggtggcggt ggctcgggcg gtggtgggtc gggtggcggc    360ggatctgagg tgcagctggt gcagagcggc cccgaggtga agaagcccgg cgccaccgtg    420aagatcagct gcaagaccag cggctacacc ttcaccgagt acaccatcca ctgggtgaag    480caggcccccg gcaagggcct ggagtggatc ggcaacatca accccaacaa cggcggcacc    540acctacaacc agaagttcga ggacaaggcc accctgaccg tggacaagag caccgacacc    600gcctacatgg agctgagcag cctgcgcagc gaggacaccg ccgtgtacta ctgcgccgcc    660ggctggaact tcgactactg gggccagggc accctactta cagtaagtag caccacgacg    720ccagcgccgc gaccaccaac accggcgccc accatcgcgt cgcagcccct gtccctgcgc    780ccagaggcgt gccggccagc ggcggggggc gcagtgcaca cgagggggct ggacttcgcc    840tgtgatatct acatctgggc gcccttggcc gggacttgtg gggtccttct cctgtcactg    900gttatcaccc tttactgcaa acggggcaga aagaaactcc tgtatatatt caaacaacca    960tttatgagac cagtacaaac tactcaagag gaagatggct gtagctgccg atttccagaa   1020gaagaagaag gaggatgtga actgtaagct agccgactgt gccttctagt tgccagccat   1080ctgttgtttg cccctccccc gtgccttcct tgaccctgga aggtgccact cccactgtcc   1140tttcctaata aaatgaggaa attgcatcgc attgtctgag taggtgtcat tctattctgg   1200ggggtggggt ggggcaggac agcaaggggg aggattggga agacaatagc aggcatgctg   1260gggatgcggt gggctctatg gcatatgcta ccgggtaggg gaggcgcttt tcccaaggca   1320gtctggagca tgcgctttag cagccccgct gggcacttgg cgctacacaa gtggcctctg   1380gcctcgcaca cattccacat ccaccggtag gcgccaaccg gctccgttct ttggtggccc   1440cttcgcgcca ccttctactc ctcccctagt caggaagttc ccccccgccc cgcagctcgc   1500gtcgtgcagg acgtgacaaa tggaagtagc acgtctcact agtctcgtgc agatggacag   1560caccgctgag caatggaagc gggtaggcct ttggggcagc ggccaatagc agctttgctc   1620cttcgctttc tgggctcaga ggctgggaag gggtgggtcc gggggcgggc tcaggggcgg   1680gctcaggggc ggggcgggcg cccgaaggtc ctccggaggc ccggcattct gcacgcttca   1740aaagcgcacg tctgccgcgc tgttctcctc ttcctcatct ccgggccttt cgactctaga   1800ccaccatgga gtttgggctg agctgggttt tcctcgttgc tctttttaga ggtgtacagt   1860gtatctggga gctgaagaag gacgtgtacg tggtggagct ggactggtac cccgacgccc   1920ccggcgagat ggtggtatta acctgcgaca ccccagagga agacggcatc acctggaccc   1980tggaccagtc aagcgaggtg ctgggtagcg gcaagaccct gaccatccag gtgaaggagt   2040tcggcgacgc cggccagtac acctgccaca agggcggcga ggtgctgagc cacagcctac   2100tgcttctcca caagaaggag gacggcatct ggagcaccga catcctgaag gaccagaagg   2160agcccaagaa caagaccttc ctgcgctgcg aggccaagaa ttactcagga cgattcacct   2220gctggtggct gaccaccatc agcaccgacc tgaccttcag cgtgaagagc agccgcggca   2280gcagcgaccc ccagggcgtg acctgcggcg ccgccaccct gagcgccgag cgcgtgcgcg   2340gcgacaacaa ggagtacgag tacagcgtgg agtgccagga ggacagcgcc tgccccgccg   2400ccgaggagag cctgcccatc gaggtgatgg tggacgccgt gcacaagctg aagtacgaga   2460actacaccag cagcttcttc atccgcgaca tcatcaagcc cgaccccccc aagaacctgc   2520agctgaagcc cctgaagaac agccgccagg tggaggtgag ctgggagtac cccgacacct   2580ggagcacccc ccacagctac ttcagcctga ccttctgcgt gcaggtgcag ggcaagagca   2640agcgcgagaa gaaggaccgc gtgttcaccg acaagaccag cgccaccgtg atctgccgca   2700agaatgcgag catcagcgtg cgcgcccagg accgctacta cagcagcagc tggagcgagt   2760gggccagcgt gccctgcagc ggaggtggcg gtggaggcag ccgcaacctg cccgtggcca   2820cccccgaccc cggcatgttc ccctgcctgc accacagcca gaacctgctg cgcgccgtga   2880gcaacatgct gcagaaggcc cgccagaccc tggagttcta cccctgcacc agcgaggaga   2940tcgaccacga ggacatcacc aaggacaaga ccagcaccgt ggaggcctgc ctgcccctgg   3000agctgaccaa gaacgagagc tgtctgaaca gcagagagac tagcttcatc actaacggca   3060gctgcctagc cagccgcaag accagcttca tgatggccct gtgcctgagc agcatctacg   3120aggacctgaa gatgtaccag gtggagttca agaccatgaa cgccaagctg ctgatggacc   3180ccaagcgcca gatcttcctg gaccagaaca tgctggccgt gatcgacgag ctgatgcagg   3240ccctgaactt caacagcgag accgtgcccc agaagagcag cctggaggag cccgacttct   3300acaagaccaa gatcaagctg tgcatcctgc tgcacgcctt ccgcatccgc gccgtgacca   3360tcgaccgcgt gatgagctac ctgaacgcat ca                                 3392</s400><s200><s210>41</s210><s211>1059</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 41gacgtggtga tgacccagag ccccctgagc ctgcccgtga cccccggcga gcccgccagc     60atcagctgcc gcagcagcca gagcctggtg cacagcaacc gcaacaccta cctgcactgg    120tacctgcaga agcccggcca gagcccccag ctgctgatct acaaggtgag caaccgcttc    180agcggcgtgc ccgaccgctt cagcggcagc ggcagcggca ccgacttcac cctgaagatc    240agccgcgtgg aggccgagga cgtgggcgtg tactactgca gccagaacac ccacgtgccc    300cccaccttcg gccagggcac caagctggag atcaagggtg gcggtggctc gggaggtgga    360gggtcgggtg gcggcggatc tcaggtgcag ctggtgcaga gcggcgccga ggtgaagaag    420cccggcgcca gcgtgaaggt gagctgcaag gccagcggct acaccttcac cgactacgag    480atgcactggg tgcgccaggc ccccggccag ggcctggagt ggatgggcgc cctggacccc    540aagaccggcg acaccgccta cagccagaag ttcaagggcc gcgtgaccct gaccgccgac    600aagagcacca gcaccgccta catggagctg agcagcctga ccagcgagga caccgccgtg    660tactactgca cccgcttcta cagctacacc tactggggcc agggcaccct ggtgaccgtg    720agcagcacca cgacgccagc gccgcgacca ccaacaccgg cgcccaccat cgcgtcgcag    780cccctgtccc tgcgcccaga ggcgtgccgg ccagcggcgg ggggcgcagt gcacacgagg    840gggctggact tcgcctgtga tatctacatc tgggcgccct tggccgggac ttgtggggtc    900cttctcctgt cactggttat caccctttac tgcaaacggg gcagaaagaa actcctgtat    960atattcaaac aaccatttat gagaccagta caaactactc aagaggaaga tggctgtagc   1020tgccgatttc cagaagaaga agaaggagga tgtgaactg                          1059</s400><s200><s210>42</s210><s211>1395</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 42gacgtggtga tgacccagag ccccctgagc ctgcccgtga cccccggcga gcccgccagc     60atcagctgcc gcagcagcca gagcctggtg cacagcaacc gcaacaccta cctgcactgg    120tacctgcaga agcccggcca gagcccccag ctgctgatct acaaggtgag caaccgcttc    180agcggcgtgc ccgaccgctt cagcggcagc ggcagcggca ccgacttcac cctgaagatc    240agccgcgtgg aggccgagga cgtgggcgtg tactactgca gccagaacac ccacgtgccc    300cccaccttcg gccagggcac caagctggag atcaagggtg gcggtggctc gggaggtgga    360gggtcgggtg gcggcggatc tcaggtgcag ctggtgcaga gcggcgccga ggtgaagaag    420cccggcgcca gcgtgaaggt gagctgcaag gccagcggct acaccttcac cgactacgag    480atgcactggg tgcgccaggc ccccggccag ggcctggagt ggatgggcgc cctggacccc    540aagaccggcg acaccgccta cagccagaag ttcaagggcc gcgtgaccct gaccgccgac    600aagagcacca gcaccgccta catggagctg agcagcctga ccagcgagga caccgccgtg    660tactactgca cccgcttcta cagctacacc tactggggcc agggcaccct ggtgaccgtg    720agcagcacca cgacgccagc gccgcgacca ccaacaccgg cgcccaccat cgcgtcgcag    780cccctgtccc tgcgcccaga ggcgtgccgg ccagcggcgg ggggcgcagt gcacacgagg    840gggctggact tcgcctgtga tatctacatc tgggcgccct tggccgggac ttgtggggtc    900cttctcctgt cactggttat caccctttac tgcaaacggg gcagaaagaa actcctgtat    960atattcaaac aaccatttat gagaccagta caaactactc aagaggaaga tggctgtagc   1020tgccgatttc cagaagaaga agaaggagga tgtgaactga gagtgaagtt cagcaggagc   1080gcagacgccc ccgcgtacaa gcagggccag aaccagctct ataacgagct caatctagga   1140cgaagagagg agtacgatgt tttggacaag agacgtggcc gggaccctga gatgggggga   1200aagccgagaa ggaagaaccc tcaggaaggc ctgtacaatg aactgcagaa agataagatg   1260gcggaggcct acagtgagat tgggatgaaa ggcgagcgcc ggaggggcaa ggggcacgat   1320ggcctttacc agggtctcag tacagccacc aaggacacct acgacgccct tcacatgcag   1380gccctgcccc ctcgc                                                    1395</s400><s200><s210>43</s210><s211>2463</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 43gacgtggtga tgacccagag ccccctgagc ctgcccgtga cccccggcga gcccgccagc     60atcagctgcc gcagcagcca gagcctggtg cacagcaacc gcaacaccta cctgcactgg    120tacctgcaga agcccggcca gagcccccag ctgctgatct acaaggtgag caaccgcttc    180agcggcgtgc ccgaccgctt cagcggcagc ggcagcggca ccgacttcac cctgaagatc    240agccgcgtgg aggccgagga cgtgggcgtg tactactgca gccagaacac ccacgtgccc    300cccaccttcg gccagggcac caagctggag atcaagggtg gcggtggctc gggaggtgga    360gggtcgggtg gcggcggatc tcaggtgcag ctggtgcaga gcggcgccga ggtgaagaag    420cccggcgcca gcgtgaaggt gagctgcaag gccagcggct acaccttcac cgactacgag    480atgcactggg tgcgccaggc ccccggccag ggcctggagt ggatgggcgc cctggacccc    540aagaccggcg acaccgccta cagccagaag ttcaagggcc gcgtgaccct gaccgccgac    600aagagcacca gcaccgccta catggagctg agcagcctga ccagcgagga caccgccgtg    660tactactgca cccgcttcta cagctacacc tactggggcc agggcaccct ggtgaccgtg    720agcagcacca cgacgccagc gccgcgacca ccaacaccgg cgcccaccat cgcgtcgcag    780cccctgtccc tgcgcccaga ggcgtgccgg ccagcggcgg ggggcgcagt gcacacgagg    840gggctggact tcgcctgtga tatctacatc tgggcgccct tggccgggac ttgtggggtc    900cttctcctgt cactggttat caccctttac tgcaaacggg gcagaaagaa actcctgtat    960atattcaaac aaccatttat gagaccagta caaactactc aagaggaaga tggctgtagc   1020tgccgatttc cagaagaaga agaaggagga tgtgaactgt aagctagccg actgtgcctt   1080ctagttgcca gccatctgtt gtttgcccct cccccgtgcc ttccttgacc ctggaaggtg   1140ccactcccac tgtcctttcc taataaaatg aggaaattgc atcgcattgt ctgagtaggt   1200gtcattctat tctggggggt ggggtggggc aggacagcaa gggggaggat tgggaagaca   1260atagcaggca tgctggggat gcggtgggct ctatggcata tgggtatcga taagcttgat   1320atcgaattag gaggaaaaac tgtttcatac agaaggcgtc aattaggagg aaaaactgtt   1380tcatacagaa ggcgtcaatt aggaggaaaa actgtttcat acagaaggcg tcaattggtc   1440ccatcgaatt aggaggaaaa actgtttcat acagaaggcg tcaattagga ggaaaaactg   1500tttcatacag aaggcgtcaa ttaggaggaa aaactgtttc atacagaagg cgtcaattgg   1560tcccgggaca ttttgacacc cccataatat ttttccagaa ttaacagtat aaattgcatc   1620tcttgttcaa gagttcccta tcactctctt taatcactac tcacagtaac ctcaactcct   1680gtctagacca ccatggacat gcgagttcct gcccaactgc ttggccttct tttgctctgg   1740ctgccaggag ccaagtgcca ggtgcagctg gtggagagtg gaggtggcgt ggtacagccc   1800ggccgcagcc tgcgcctgga ctgcaaggcc agcggcatca ccttcagcaa cagcggcatg   1860cactgggtgc gccaggcccc cggcaagggc ctggagtggg tggccgtgat ctggtacgac   1920ggcagcaagc gctactacgc cgacagcgtg aagggccgct tcaccatcag ccgcgacaac   1980agcaagaaca ccctgttcct gcagatgaac agcctgcgcg ccgaggacac cgccgtgtac   2040tactgcgcca ccaacgacga ctactggggc cagggcaccc tggtgaccgt gagcagcggt   2100ggcggtggct cgggcggtgg tgggtcgggt ggcggcggat ctgagatcgt gctgacccag   2160agccccgcca ccctgagcct gagccccggc gagcgcgcca ccctgagctg ccgcgccagc   2220cagagcgtga gcagctacct ggcctggtac cagcagaagc caggacaggc tccacgactg   2280ctaatctatg acgccagcaa ccgcgccacc ggcatccccg cccgcttcag cggcagcggc   2340agcggcaccg acttcaccct gaccatcagc agcctggagc ccgaggactt cgccgtgtac   2400tactgccagc agagcagcaa ctggccccgc accttcggcc agggcaccaa ggtggagatc   2460aag                                                                 2463</s400><s200><s210>44</s210><s211>2799</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 44gacgtggtga tgacccagag ccccctgagc ctgcccgtga cccccggcga gcccgccagc     60atcagctgcc gcagcagcca gagcctggtg cacagcaacc gcaacaccta cctgcactgg    120tacctgcaga agcccggcca gagcccccag ctgctgatct acaaggtgag caaccgcttc    180agcggcgtgc ccgaccgctt cagcggcagc ggcagcggca ccgacttcac cctgaagatc    240agccgcgtgg aggccgagga cgtgggcgtg tactactgca gccagaacac ccacgtgccc    300cccaccttcg gccagggcac caagctggag atcaagggtg gcggtggctc gggaggtgga    360gggtcgggtg gcggcggatc tcaggtgcag ctggtgcaga gcggcgccga ggtgaagaag    420cccggcgcca gcgtgaaggt gagctgcaag gccagcggct acaccttcac cgactacgag    480atgcactggg tgcgccaggc ccccggccag ggcctggagt ggatgggcgc cctggacccc    540aagaccggcg acaccgccta cagccagaag ttcaagggcc gcgtgaccct gaccgccgac    600aagagcacca gcaccgccta catggagctg agcagcctga ccagcgagga caccgccgtg    660tactactgca cccgcttcta cagctacacc tactggggcc agggcaccct ggtgaccgtg    720agcagcacca cgacgccagc gccgcgacca ccaacaccgg cgcccaccat cgcgtcgcag    780cccctgtccc tgcgcccaga ggcgtgccgg ccagcggcgg ggggcgcagt gcacacgagg    840gggctggact tcgcctgtga tatctacatc tgggcgccct tggccgggac ttgtggggtc    900cttctcctgt cactggttat caccctttac tgcaaacggg gcagaaagaa actcctgtat    960atattcaaac aaccatttat gagaccagta caaactactc aagaggaaga tggctgtagc   1020tgccgatttc cagaagaaga agaaggagga tgtgaactga gagtgaagtt cagcaggagc   1080gcagacgccc ccgcgtacaa gcagggccag aaccagctct ataacgagct caatctagga   1140cgaagagagg agtacgatgt tttggacaag agacgtggcc gggaccctga gatgggggga   1200aagccgagaa ggaagaaccc tcaggaaggc ctgtacaatg aactgcagaa agataagatg   1260gcggaggcct acagtgagat tgggatgaaa ggcgagcgcc ggaggggcaa ggggcacgat   1320ggcctttacc agggtctcag tacagccacc aaggacacct acgacgccct tcacatgcag   1380gccctgcccc ctcgctaagc tagccgactg tgccttctag ttgccagcca tctgttgttt   1440gcccctcccc cgtgccttcc ttgaccctgg aaggtgccac tcccactgtc ctttcctaat   1500aaaatgagga aattgcatcg cattgtctga gtaggtgtca ttctattctg gggggtgggg   1560tggggcagga cagcaagggg gaggattggg aagacaatag caggcatgct ggggatgcgg   1620tgggctctat ggcatatggg tatcgataag cttgatatcg aattaggagg aaaaactgtt   1680tcatacagaa ggcgtcaatt aggaggaaaa actgtttcat acagaaggcg tcaattagga   1740ggaaaaactg tttcatacag aaggcgtcaa ttggtcccat cgaattagga ggaaaaactg   1800tttcatacag aaggcgtcaa ttaggaggaa aaactgtttc atacagaagg cgtcaattag   1860gaggaaaaac tgtttcatac agaaggcgtc aattggtccc gggacatttt gacaccccca   1920taatattttt ccagaattaa cagtataaat tgcatctctt gttcaagagt tccctatcac   1980tctctttaat cactactcac agtaacctca actcctgtct agaccaccat ggacatgcga   2040gttcctgccc aactgcttgg ccttcttttg ctctggctgc caggagccaa gtgccaggtg   2100cagctggtgg agagtggagg tggcgtggta cagcccggcc gcagcctgcg cctggactgc   2160aaggccagcg gcatcacctt cagcaacagc ggcatgcact gggtgcgcca ggcccccggc   2220aagggcctgg agtgggtggc cgtgatctgg tacgacggca gcaagcgcta ctacgccgac   2280agcgtgaagg gccgcttcac catcagccgc gacaacagca agaacaccct gttcctgcag   2340atgaacagcc tgcgcgccga ggacaccgcc gtgtactact gcgccaccaa cgacgactac   2400tggggccagg gcaccctggt gaccgtgagc agcggtggcg gtggctcggg cggtggtggg   2460tcgggtggcg gcggatctga gatcgtgctg acccagagcc ccgccaccct gagcctgagc   2520cccggcgagc gcgccaccct gagctgccgc gccagccaga gcgtgagcag ctacctggcc   2580tggtaccagc agaagccagg acaggctcca cgactgctaa tctatgacgc cagcaaccgc   2640gccaccggca tccccgcccg cttcagcggc agcggcagcg gcaccgactt caccctgacc   2700atcagcagcc tggagcccga ggacttcgcc gtgtactact gccagcagag cagcaactgg   2760ccccgcacct tcggccaggg caccaaggtg gagatcaag                          2799</s400><s200><s210>45</s210><s211>2478</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 45gacgtggtga tgacccagag ccccctgagc ctgcccgtga cccccggcga gcccgccagc     60atcagctgcc gcagcagcca gagcctggtg cacagcaacc gcaacaccta cctgcactgg    120tacctgcaga agcccggcca gagcccccag ctgctgatct acaaggtgag caaccgcttc    180agcggcgtgc ccgaccgctt cagcggcagc ggcagcggca ccgacttcac cctgaagatc    240agccgcgtgg aggccgagga cgtgggcgtg tactactgca gccagaacac ccacgtgccc    300cccaccttcg gccagggcac caagctggag atcaagggtg gcggtggctc gggaggtgga    360gggtcgggtg gcggcggatc tcaggtgcag ctggtgcaga gcggcgccga ggtgaagaag    420cccggcgcca gcgtgaaggt gagctgcaag gccagcggct acaccttcac cgactacgag    480atgcactggg tgcgccaggc ccccggccag ggcctggagt ggatgggcgc cctggacccc    540aagaccggcg acaccgccta cagccagaag ttcaagggcc gcgtgaccct gaccgccgac    600aagagcacca gcaccgccta catggagctg agcagcctga ccagcgagga caccgccgtg    660tactactgca cccgcttcta cagctacacc tactggggcc agggcaccct ggtgaccgtg    720agcagcacca cgacgccagc gccgcgacca ccaacaccgg cgcccaccat cgcgtcgcag    780cccctgtccc tgcgcccaga ggcgtgccgg ccagcggcgg ggggcgcagt gcacacgagg    840gggctggact tcgcctgtga tatctacatc tgggcgccct tggccgggac ttgtggggtc    900cttctcctgt cactggttat caccctttac tgcaaacggg gcagaaagaa actcctgtat    960atattcaaac aaccatttat gagaccagta caaactactc aagaggaaga tggctgtagc   1020tgccgatttc cagaagaaga agaaggagga tgtgaactgt aagctagccg actgtgcctt   1080ctagttgcca gccatctgtt gtttgcccct cccccgtgcc ttccttgacc ctggaaggtg   1140ccactcccac tgtcctttcc taataaaatg aggaaattgc atcgcattgt ctgagtaggt   1200gtcattctat tctggggggt ggggtggggc aggacagcaa gggggaggat tgggaagaca   1260atagcaggca tgctggggat gcggtgggct ctatggcata tgggtatcga taagcttgat   1320atcgaattag gaggaaaaac tgtttcatac agaaggcgtc aattaggagg aaaaactgtt   1380tcatacagaa ggcgtcaatt aggaggaaaa actgtttcat acagaaggcg tcaattggtc   1440ccatcgaatt aggaggaaaa actgtttcat acagaaggcg tcaattagga ggaaaaactg   1500tttcatacag aaggcgtcaa ttaggaggaa aaactgtttc atacagaagg cgtcaattgg   1560tcccgggaca ttttgacacc cccataatat ttttccagaa ttaacagtat aaattgcatc   1620tcttgttcaa gagttcccta tcactctctt taatcactac tcacagtaac ctcaactcct   1680gtctagacca ccatggacat gcgagttcct gcccaactgc ttggccttct tttgctctgg   1740ctgccaggag ccaagtgcga ggtgcagctg gtggagagcg gaggtggact agtacagcct   1800ggtggcagcc tacgactgag ttgcgccgcc agcggcttca ccttcagcga cagctggatc   1860cactgggtgc gccaggcccc cggcaagggc ctggagtggg tggcctggat cagcccctac   1920ggcggcagca cctactacgc cgacagcgtg aagggccgct tcaccatcag cgccgacacc   1980agcaagaaca ccgcctacct gcagatgaac agcctgcgcg ccgaggacac cgccgtgtac   2040tactgcgccc gccgccactg gcccggcggc ttcgactact ggggccaggg caccctggtg   2100accgtgagca gcggaggcgg gggaagcggc ggcggagggt ctggaggagg gggcagtgac   2160atccagatga cccagagccc cagcagcctg agcgccagcg tgggcgaccg cgtgaccatc   2220acctgccgcg ccagccagga cgtgagcacc gccgtggcct ggtaccagca gaagcccggc   2280aaggccccca agctgctgat ctacagcgcc agcttcctgt acagcggcgt gcccagccgc   2340ttcagcggca gcggcagcgg caccgacttc accctgacca tcagcagcct gcagcccgag   2400gacttcgcca cctactactg ccagcagtac ctgtaccacc ccgccacctt cggccagggc   2460accaaggtgg agatcaag                                                 2478</s400><s200><s210>46</s210><s211>2814</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 46gacgtggtga tgacccagag ccccctgagc ctgcccgtga cccccggcga gcccgccagc     60atcagctgcc gcagcagcca gagcctggtg cacagcaacc gcaacaccta cctgcactgg    120tacctgcaga agcccggcca gagcccccag ctgctgatct acaaggtgag caaccgcttc    180agcggcgtgc ccgaccgctt cagcggcagc ggcagcggca ccgacttcac cctgaagatc    240agccgcgtgg aggccgagga cgtgggcgtg tactactgca gccagaacac ccacgtgccc    300cccaccttcg gccagggcac caagctggag atcaagggtg gcggtggctc gggaggtgga    360gggtcgggtg gcggcggatc tcaggtgcag ctggtgcaga gcggcgccga ggtgaagaag    420cccggcgcca gcgtgaaggt gagctgcaag gccagcggct acaccttcac cgactacgag    480atgcactggg tgcgccaggc ccccggccag ggcctggagt ggatgggcgc cctggacccc    540aagaccggcg acaccgccta cagccagaag ttcaagggcc gcgtgaccct gaccgccgac    600aagagcacca gcaccgccta catggagctg agcagcctga ccagcgagga caccgccgtg    660tactactgca cccgcttcta cagctacacc tactggggcc agggcaccct ggtgaccgtg    720agcagcacca cgacgccagc gccgcgacca ccaacaccgg cgcccaccat cgcgtcgcag    780cccctgtccc tgcgcccaga ggcgtgccgg ccagcggcgg ggggcgcagt gcacacgagg    840gggctggact tcgcctgtga tatctacatc tgggcgccct tggccgggac ttgtggggtc    900cttctcctgt cactggttat caccctttac tgcaaacggg gcagaaagaa actcctgtat    960atattcaaac aaccatttat gagaccagta caaactactc aagaggaaga tggctgtagc   1020tgccgatttc cagaagaaga agaaggagga tgtgaactga gagtgaagtt cagcaggagc   1080gcagacgccc ccgcgtacaa gcagggccag aaccagctct ataacgagct caatctagga   1140cgaagagagg agtacgatgt tttggacaag agacgtggcc gggaccctga gatgggggga   1200aagccgagaa ggaagaaccc tcaggaaggc ctgtacaatg aactgcagaa agataagatg   1260gcggaggcct acagtgagat tgggatgaaa ggcgagcgcc ggaggggcaa ggggcacgat   1320ggcctttacc agggtctcag tacagccacc aaggacacct acgacgccct tcacatgcag   1380gccctgcccc ctcgctaagc tagccgactg tgccttctag ttgccagcca tctgttgttt   1440gcccctcccc cgtgccttcc ttgaccctgg aaggtgccac tcccactgtc ctttcctaat   1500aaaatgagga aattgcatcg cattgtctga gtaggtgtca ttctattctg gggggtgggg   1560tggggcagga cagcaagggg gaggattggg aagacaatag caggcatgct ggggatgcgg   1620tgggctctat ggcatatggg tatcgataag cttgatatcg aattaggagg aaaaactgtt   1680tcatacagaa ggcgtcaatt aggaggaaaa actgtttcat acagaaggcg tcaattagga   1740ggaaaaactg tttcatacag aaggcgtcaa ttggtcccat cgaattagga ggaaaaactg   1800tttcatacag aaggcgtcaa ttaggaggaa aaactgtttc atacagaagg cgtcaattag   1860gaggaaaaac tgtttcatac agaaggcgtc aattggtccc gggacatttt gacaccccca   1920taatattttt ccagaattaa cagtataaat tgcatctctt gttcaagagt tccctatcac   1980tctctttaat cactactcac agtaacctca actcctgtct agaccaccat ggacatgcga   2040gttcctgccc aactgcttgg ccttcttttg ctctggctgc caggagccaa gtgcgaggtg   2100cagctggtgg agagcggagg tggactagta cagcctggtg gcagcctacg actgagttgc   2160gccgccagcg gcttcacctt cagcgacagc tggatccact gggtgcgcca ggcccccggc   2220aagggcctgg agtgggtggc ctggatcagc ccctacggcg gcagcaccta ctacgccgac   2280agcgtgaagg gccgcttcac catcagcgcc gacaccagca agaacaccgc ctacctgcag   2340atgaacagcc tgcgcgccga ggacaccgcc gtgtactact gcgcccgccg ccactggccc   2400ggcggcttcg actactgggg ccagggcacc ctggtgaccg tgagcagcgg aggcggggga   2460agcggcggcg gagggtctgg aggagggggc agtgacatcc agatgaccca gagccccagc   2520agcctgagcg ccagcgtggg cgaccgcgtg accatcacct gccgcgccag ccaggacgtg   2580agcaccgccg tggcctggta ccagcagaag cccggcaagg cccccaagct gctgatctac   2640agcgccagct tcctgtacag cggcgtgccc agccgcttca gcggcagcgg cagcggcacc   2700gacttcaccc tgaccatcag cagcctgcag cccgaggact tcgccaccta ctactgccag   2760cagtacctgt accaccccgc caccttcggc cagggcacca aggtggagat caag         2814</s400><s200><s210>47</s210><s211>2591</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 47gacgtggtga tgacccagag ccccctgagc ctgcccgtga cccccggcga gcccgccagc     60atcagctgcc gcagcagcca gagcctggtg cacagcaacc gcaacaccta cctgcactgg    120tacctgcaga agcccggcca gagcccccag ctgctgatct acaaggtgag caaccgcttc    180agcggcgtgc ccgaccgctt cagcggcagc ggcagcggca ccgacttcac cctgaagatc    240agccgcgtgg aggccgagga cgtgggcgtg tactactgca gccagaacac ccacgtgccc    300cccaccttcg gccagggcac caagctggag atcaagggtg gcggtggctc gggaggtgga    360gggtcgggtg gcggcggatc tcaggtgcag ctggtgcaga gcggcgccga ggtgaagaag    420cccggcgcca gcgtgaaggt gagctgcaag gccagcggct acaccttcac cgactacgag    480atgcactggg tgcgccaggc ccccggccag ggcctggagt ggatgggcgc cctggacccc    540aagaccggcg acaccgccta cagccagaag ttcaagggcc gcgtgaccct gaccgccgac    600aagagcacca gcaccgccta catggagctg agcagcctga ccagcgagga caccgccgtg    660tactactgca cccgcttcta cagctacacc tactggggcc agggcaccct ggtgaccgtg    720agcagcacca cgacgccagc gccgcgacca ccaacaccgg cgcccaccat cgcgtcgcag    780cccctgtccc tgcgcccaga ggcgtgccgg ccagcggcgg ggggcgcagt gcacacgagg    840gggctggact tcgcctgtga tatctacatc tgggcgccct tggccgggac ttgtggggtc    900cttctcctgt cactggttat caccctttac tgcaaacggg gcagaaagaa actcctgtat    960atattcaaac aaccatttat gagaccagta caaactactc aagaggaaga tggctgtagc   1020tgccgatttc cagaagaaga agaaggagga tgtgaactgt aagctagccg actgtgcctt   1080ctagttgcca gccatctgtt gtttgcccct cccccgtgcc ttccttgacc ctggaaggtg   1140ccactcccac tgtcctttcc taataaaatg aggaaattgc atcgcattgt ctgagtaggt   1200gtcattctat tctggggggt ggggtggggc aggacagcaa gggggaggat tgggaagaca   1260atagcaggca tgctggggat gcggtgggct ctatggcata tgctaccggg taggggaggc   1320gcttttccca aggcagtctg gagcatgcgc tttagcagcc ccgctgggca cttggcgcta   1380cacaagtggc ctctggcctc gcacacattc cacatccacc ggtaggcgcc aaccggctcc   1440gttctttggt ggccccttcg cgccaccttc tactcctccc ctagtcagga agttcccccc   1500cgccccgcag ctcgcgtcgt gcaggacgtg acaaatggaa gtagcacgtc tcactagtct   1560cgtgcagatg gacagcaccg ctgagcaatg gaagcgggta ggcctttggg gcagcggcca   1620atagcagctt tgctccttcg ctttctgggc tcagaggctg ggaaggggtg ggtccggggg   1680cgggctcagg ggcgggctca ggggcggggc gggcgcccga aggtcctccg gaggcccggc   1740attctgcacg cttcaaaagc gcacgtctgc cgcgctgttc tcctcttcct catctccggg   1800cctttcgact ctagaccacc atggacatgc gagttcctgc ccaactgctt ggccttcttt   1860tgctctggct gccaggagcc aagtgccagg tgcagctggt ggagagtgga ggtggcgtgg   1920tacagcccgg ccgcagcctg cgcctggact gcaaggccag cggcatcacc ttcagcaaca   1980gcggcatgca ctgggtgcgc caggcccccg gcaagggcct ggagtgggtg gccgtgatct   2040ggtacgacgg cagcaagcgc tactacgccg acagcgtgaa gggccgcttc accatcagcc   2100gcgacaacag caagaacacc ctgttcctgc agatgaacag cctgcgcgcc gaggacaccg   2160ccgtgtacta ctgcgccacc aacgacgact actggggcca gggcaccctg gtgaccgtga   2220gcagcggtgg cggtggctcg ggcggtggtg ggtcgggtgg cggcggatct gagatcgtgc   2280tgacccagag ccccgccacc ctgagcctga gccccggcga gcgcgccacc ctgagctgcc   2340gcgccagcca gagcgtgagc agctacctgg cctggtacca gcagaagcca ggacaggctc   2400cacgactgct aatctatgac gccagcaacc gcgccaccgg catccccgcc cgcttcagcg   2460gcagcggcag cggcaccgac ttcaccctga ccatcagcag cctggagccc gaggacttcg   2520ccgtgtacta ctgccagcag agcagcaact ggccccgcac cttcggccag ggcaccaagg   2580tggagatcaa g                                                        2591</s400><s200><s210>48</s210><s211>1920</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 48gacgtggtga tgacccagag ccccctgagc ctgcccgtga cccccggcga gcccgccagc     60atcagctgcc gcagcagcca gagcctggtg cacagcaacc gcaacaccta cctgcactgg    120tacctgcaga agcccggcca gagcccccag ctgctgatct acaaggtgag caaccgcttc    180agcggcgtgc ccgaccgctt cagcggcagc ggcagcggca ccgacttcac cctgaagatc    240agccgcgtgg aggccgagga cgtgggcgtg tactactgca gccagaacac ccacgtgccc    300cccaccttcg gccagggcac caagctggag atcaagggtg gcggtggctc gggaggtgga    360gggtcgggtg gcggcggatc tcaggtgcag ctggtgcaga gcggcgccga ggtgaagaag    420cccggcgcca gcgtgaaggt gagctgcaag gccagcggct acaccttcac cgactacgag    480atgcactggg tgcgccaggc ccccggccag ggcctggagt ggatgggcgc cctggacccc    540aagaccggcg acaccgccta cagccagaag ttcaagggcc gcgtgaccct gaccgccgac    600aagagcacca gcaccgccta catggagctg agcagcctga ccagcgagga caccgccgtg    660tactactgca cccgcttcta cagctacacc tactggggcc agggcaccct ggtgaccgtg    720agcagcacca cgacgccagc gccgcgacca ccaacaccgg cgcccaccat cgcgtcgcag    780cccctgtccc tgcgcccaga ggcgtgccgg ccagcggcgg ggggcgcagt gcacacgagg    840gggctggact tcgcctgtga tatctacatc tgggcgccct tggccgggac ttgtggggtc    900cttctcctgt cactggttat caccctttac tgcaaacggg gcagaaagaa actcctgtat    960atattcaaac aaccatttat gagaccagta caaactactc aagaggaaga tggctgtagc   1020tgccgatttc cagaagaaga agaaggagga tgtgaactgg ctagccatat gggcagcggc   1080gccaccaact tcagcctgct gaagcaggcc ggcgacgtgg aggagaaccc cggcccctct   1140agagccacca tggacatgcg agttcctgcc caactgcttg gccttctttt gctctggctg   1200ccaggagcca agtgccaggt gcagctggtg gagagtggag gtggcgtggt acagcccggc   1260cgcagcctgc gcctggactg caaggccagc ggcatcacct tcagcaacag cggcatgcac   1320tgggtgcgcc aggcccccgg caagggcctg gagtgggtgg ccgtgatctg gtacgacggc   1380agcaagcgct actacgccga cagcgtgaag ggccgcttca ccatcagccg cgacaacagc   1440aagaacaccc tgttcctgca gatgaacagc ctgcgcgccg aggacaccgc cgtgtactac   1500tgcgccacca acgacgacta ctggggccag ggcaccctgg tgaccgtgag cagcggtggc   1560ggtggctcgg gcggtggtgg gtcgggtggc ggcggatctg agatcgtgct gacccagagc   1620cccgccaccc tgagcctgag ccccggcgag cgcgccaccc tgagctgccg cgccagccag   1680agcgtgagca gctacctggc ctggtaccag cagaagccag gacaggctcc acgactgcta   1740atctatgacg ccagcaaccg cgccaccggc atccccgccc gcttcagcgg cagcggcagc   1800ggcaccgact tcaccctgac catcagcagc ctggagcccg aggacttcgc cgtgtactac   1860tgccagcaga gcagcaactg gccccgcacc ttcggccagg gcaccaaggt ggagatcaag   1920</s400><s200><s210>49</s210><s211>2148</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 49gacgtggtga tgacccagag ccccctgagc ctgcccgtga cccccggcga gcccgccagc     60atcagctgcc gcagcagcca gagcctggtg cacagcaacc gcaacaccta cctgcactgg    120tacctgcaga agcccggcca gagcccccag ctgctgatct acaaggtgag caaccgcttc    180agcggcgtgc ccgaccgctt cagcggcagc ggcagcggca ccgacttcac cctgaagatc    240agccgcgtgg aggccgagga cgtgggcgtg tactactgca gccagaacac ccacgtgccc    300cccaccttcg gccagggcac caagctggag atcaagggtg gcggtggctc gggaggtgga    360gggtcgggtg gcggcggatc tcaggtgcag ctggtgcaga gcggcgccga ggtgaagaag    420cccggcgcca gcgtgaaggt gagctgcaag gccagcggct acaccttcac cgactacgag    480atgcactggg tgcgccaggc ccccggccag ggcctggagt ggatgggcgc cctggacccc    540aagaccggcg acaccgccta cagccagaag ttcaagggcc gcgtgaccct gaccgccgac    600aagagcacca gcaccgccta catggagctg agcagcctga ccagcgagga caccgccgtg    660tactactgca cccgcttcta cagctacacc tactggggcc agggcaccct ggtgaccgtg    720agcagcacca cgacgccagc gccgcgacca ccaacaccgg cgcccaccat cgcgtcgcag    780cccctgtccc tgcgcccaga ggcgtgccgg ccagcggcgg ggggcgcagt gcacacgagg    840gggctggact tcgcctgtga tatctacatc tgggcgccct tggccgggac ttgtggggtc    900cttctcctgt cactggttat caccctttac tgcaaacggg gcagaaagaa actcctgtat    960atattcaaac aaccatttat gagaccagta caaactactc aagaggaaga tggctgtagc   1020tgccgatttc cagaagaaga agaaggagga tgtgaactgt aagctagccg actgtgcctt   1080ctagttgcca gccatctgtt gtttgcccct cccccgtgcc ttccttgacc ctggaaggtg   1140ccactcccac tgtcctttcc taataaaatg aggaaattgc atcgcattgt ctgagtaggt   1200gtcattctat tctggggggt ggggtggggc aggacagcaa gggggaggat tgggaagaca   1260atagcaggca tgctggggat gcggtgggct ctatggcata tgggtatcga taagcttgat   1320atcgaattag gaggaaaaac tgtttcatac agaaggcgtc aattaggagg aaaaactgtt   1380tcatacagaa ggcgtcaatt aggaggaaaa actgtttcat acagaaggcg tcaattggtc   1440ccatcgaatt aggaggaaaa actgtttcat acagaaggcg tcaattagga ggaaaaactg   1500tttcatacag aaggcgtcaa ttaggaggaa aaactgtttc atacagaagg cgtcaattgg   1560tcccgggaca ttttgacacc cccataatat ttttccagaa ttaacagtat aaattgcatc   1620tcttgttcaa gagttcccta tcactctctt taatcactac tcacagtaac ctcaactcct   1680gtctagacca ccatggagtt tgggctgagc tgggttttcc tcgttgctct ttttagaggt   1740gtacagtgtg ccccaaccag ctcaagtact aagaagacac agctgcagct ggagcacctg   1800ctgctggacc tgcagatgat cctgaacggc atcaacaact acaagaaccc caagctgacc   1860cgcatgctga ccttcaagtt ctacatgccc aagaaggcca ccgagctgaa gcacctgcag   1920tgcctggagg aggagctgaa gcccctggag gaggtgctga acctggccca gagcaagaac   1980ttccacctgc gcccccgcga cctgatcagc aacatcaacg tgatcgtgct ggagctgaag   2040ggcagcgaga ccaccttcat gtgcgagtac gccgacgaga ccgccaccat cgtggagttc   2100ctgaaccgct ggatcacctt ctgccagagc atcatcagca ccctgacc                2148</s400><s200><s210>50</s210><s211>4263</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 50gacgtggtga tgacccagag ccccctgagc ctgcccgtga cccccggcga gcccgccagc     60atcagctgcc gcagcagcca gagcctggtg cacagcaacc gcaacaccta cctgcactgg    120tacctgcaga agcccggcca gagcccccag ctgctgatct acaaggtgag caaccgcttc    180agcggcgtgc ccgaccgctt cagcggcagc ggcagcggca ccgacttcac cctgaagatc    240agccgcgtgg aggccgagga cgtgggcgtg tactactgca gccagaacac ccacgtgccc    300cccaccttcg gccagggcac caagctggag atcaagggtg gcggtggctc gggaggtgga    360gggtcgggtg gcggcggatc tcaggtgcag ctggtgcaga gcggcgccga ggtgaagaag    420cccggcgcca gcgtgaaggt gagctgcaag gccagcggct acaccttcac cgactacgag    480atgcactggg tgcgccaggc ccccggccag ggcctggagt ggatgggcgc cctggacccc    540aagaccggcg acaccgccta cagccagaag ttcaagggcc gcgtgaccct gaccgccgac    600aagagcacca gcaccgccta catggagctg agcagcctga ccagcgagga caccgccgtg    660tactactgca cccgcttcta cagctacacc tactggggcc agggcaccct ggtgaccgtg    720agcagcacca cgacgccagc gccgcgacca ccaacaccgg cgcccaccat cgcgtcgcag    780cccctgtccc tgcgcccaga ggcgtgccgg ccagcggcgg ggggcgcagt gcacacgagg    840gggctggact tcgcctgtga tatctacatc tgggcgccct tggccgggac ttgtggggtc    900cttctcctgt cactggttat caccctttac tgcaaacggg gcagaaagaa actcctgtat    960atattcaaac aaccatttat gagaccagta caaactactc aagaggaaga tggctgtagc   1020tgccgatttc cagaagaaga agaaggagga tgtgaactgt aagctagccg actgtgcctt   1080ctagttgcca gccatctgtt gtttgcccct cccccgtgcc ttccttgacc ctggaaggtg   1140ccactcccac tgtcctttcc taataaaatg aggaaattgc atcgcattgt ctgagtaggt   1200gtcattctat tctggggggt ggggtggggc aggacagcaa gggggaggat tgggaagaca   1260atagcaggca tgctggggat gcggtgggct ctatggcata tgctaccggg taggggaggc   1320gcttttccca aggcagtctg gagcatgcgc tttagcagcc ccgctgggca cttggcgcta   1380cacaagtggc ctctggcctc gcacacattc cacatccacc ggtaggcgcc aaccggctcc   1440gttctttggt ggccccttcg cgccaccttc tactcctccc ctagtcagga agttcccccc   1500cgccccgcag ctcgcgtcgt gcaggacgtg acaaatggaa gtagcacgtc tcactagtct   1560cgtgcagatg gacagcaccg ctgagcaatg gaagcgggta ggcctttggg gcagcggcca   1620atagcagctt tgctccttcg ctttctgggc tcagaggctg ggaaggggtg ggtccggggg   1680cgggctcagg ggcgggctca ggggcggggc gggcgcccga aggtcctccg gaggcccggc   1740attctgcacg cttcaaaagc gcacgtctgc cgcgctgttc tcctcttcct catctccggg   1800cctttcgaca tctagaccac catggagttt gggctgagct gggttttcct cgttgctctt   1860tttagaggtg tacagtgtat ctgggagctg aagaaggacg tgtacgtggt ggagctggac   1920tggtaccccg acgcccccgg cgagatggtg gtattaacct gcgacacccc agaggaagac   1980ggcatcacct ggaccctgga ccagtcaagc gaggtgctgg gtagcggcaa gaccctgacc   2040atccaggtga aggagttcgg cgacgccggc cagtacacct gccacaaggg cggcgaggtg   2100ctgagccaca gcctactgct tctccacaag aaggaggacg gcatctggag caccgacatc   2160ctgaaggacc agaaggagcc caagaacaag accttcctgc gctgcgaggc caagaattac   2220tcaggacgat tcacctgctg gtggctgacc accatcagca ccgacctgac cttcagcgtg   2280aagagcagcc gcggcagcag cgacccccag ggcgtgacct gcggcgccgc caccctgagc   2340gccgagcgcg tgcgcggcga caacaaggag tacgagtaca gcgtggagtg ccaggaggac   2400agcgcctgcc ccgccgccga ggagagcctg cccatcgagg tgatggtgga cgccgtgcac   2460aagctgaagt acgagaacta caccagcagc ttcttcatcc gcgacatcat caagcccgac   2520ccccccaaga acctgcagct gaagcccctg aagaacagcc gccaggtgga ggtgagctgg   2580gagtaccccg acacctggag caccccccac agctacttca gcctgacctt ctgcgtgcag   2640gtgcagggca agagcaagcg cgagaagaag gaccgcgtgt tcaccgacaa gaccagcgcc   2700accgtgatct gccgcaagaa tgcgagcatc agcgtgcgcg cccaggaccg ctactacagc   2760agcagctgga gcgagtgggc cagcgtgccc tgcagcggag gtggcggtgg aggcagccgc   2820aacctgcccg tggccacccc cgaccccggc atgttcccct gcctgcacca cagccagaac   2880ctgctgcgcg ccgtgagcaa catgctgcag aaggcccgcc agaccctgga gttctacccc   2940tgcaccagcg aggagatcga ccacgaggac atcaccaagg acaagaccag caccgtggag   3000gcctgcctgc ccctggagct gaccaagaac gagagctgtc tgaacagcag agagactagc   3060ttcatcacta acggcagctg cctagccagc cgcaagacca gcttcatgat ggccctgtgc   3120ctgagcagca tctacgagga cctgaagatg taccaggtgg agttcaagac catgaacgcc   3180aagctgctga tggaccccaa gcgccagatc ttcctggacc agaacatgct ggccgtgatc   3240gacgagctga tgcaggccct gaacttcaac agcgagaccg tgccccagaa gagcagcctg   3300gaggagcccg acttctacaa gaccaagatc aagctgtgca tcctgctgca cgccttccgc   3360atccgcgccg tgaccatcga ccgcgtgatg agctacctga acgcatcagt taacggcagc   3420ggcgccacca acttcagcct gctgaagcag gccggcgacg tggaggagaa ccccggcccc   3480tacgtagcca ccatggacat gcgagttcct gcccaactgc ttggccttct tttgctctgg   3540ctgccaggag ccaagtgcca ggtgcagctg gtggagagtg gaggtggcgt ggtacagccc   3600ggccgcagcc tgcgcctgga ctgcaaggcc agcggcatca ccttcagcaa cagcggcatg   3660cactgggtgc gccaggcccc cggcaagggc ctggagtggg tggccgtgat ctggtacgac   3720ggcagcaagc gctactacgc cgacagcgtg aagggccgct tcaccatcag ccgcgacaac   3780agcaagaaca ccctgttcct gcagatgaac agcctgcgcg ccgaggacac cgccgtgtac   3840tactgcgcca ccaacgacga ctactggggc cagggcaccc tggtgaccgt gagcagcggt   3900ggcggtggct cgggcggtgg tgggtcgggt ggcggcggat ctgagatcgt gctgacccag   3960agccccgcca ccctgagcct gagccccggc gagcgcgcca ccctgagctg ccgcgccagc   4020cagagcgtga gcagctacct ggcctggtac cagcagaagc caggacaggc tccacgactg   4080ctaatctatg acgccagcaa ccgcgccacc ggcatccccg cccgcttcag cggcagcggc   4140agcggcaccg acttcaccct gaccatcagc agcctggagc ccgaggactt cgccgtgtac   4200tactgccagc agagcagcaa ctggccccgc accttcggcc agggcaccaa ggtggagatc   4260aag                                                                 4263</s400><s200><s210>51</s210><s211>4134</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 51gacgtggtga tgacccagag ccccctgagc ctgcccgtga cccccggcga gcccgccagc     60atcagctgcc gcagcagcca gagcctggtg cacagcaacc gcaacaccta cctgcactgg    120tacctgcaga agcccggcca gagcccccag ctgctgatct acaaggtgag caaccgcttc    180agcggcgtgc ccgaccgctt cagcggcagc ggcagcggca ccgacttcac cctgaagatc    240agccgcgtgg aggccgagga cgtgggcgtg tactactgca gccagaacac ccacgtgccc    300cccaccttcg gccagggcac caagctggag atcaagggtg gcggtggctc gggaggtgga    360gggtcgggtg gcggcggatc tcaggtgcag ctggtgcaga gcggcgccga ggtgaagaag    420cccggcgcca gcgtgaaggt gagctgcaag gccagcggct acaccttcac cgactacgag    480atgcactggg tgcgccaggc ccccggccag ggcctggagt ggatgggcgc cctggacccc    540aagaccggcg acaccgccta cagccagaag ttcaagggcc gcgtgaccct gaccgccgac    600aagagcacca gcaccgccta catggagctg agcagcctga ccagcgagga caccgccgtg    660tactactgca cccgcttcta cagctacacc tactggggcc agggcaccct ggtgaccgtg    720agcagcacca cgacgccagc gccgcgacca ccaacaccgg cgcccaccat cgcgtcgcag    780cccctgtccc tgcgcccaga ggcgtgccgg ccagcggcgg ggggcgcagt gcacacgagg    840gggctggact tcgcctgtga tatctacatc tgggcgccct tggccgggac ttgtggggtc    900cttctcctgt cactggttat caccctttac tgcaaacggg gcagaaagaa actcctgtat    960atattcaaac aaccatttat gagaccagta caaactactc aagaggaaga tggctgtagc   1020tgccgatttc cagaagaaga agaaggagga tgtgaactgt aagctagccg actgtgcctt   1080ctagttgcca gccatctgtt gtttgcccct cccccgtgcc ttccttgacc ctggaaggtg   1140ccactcccac tgtcctttcc taataaaatg aggaaattgc atcgcattgt ctgagtaggt   1200gtcattctat tctggggggt ggggtggggc aggacagcaa gggggaggat tgggaagaca   1260atagcaggca tgctggggat gcggtgggct ctatggcata tgggtatcga taagcttgat   1320atcgaattag gaggaaaaac tgtttcatac agaaggcgtc aattaggagg aaaaactgtt   1380tcatacagaa ggcgtcaatt aggaggaaaa actgtttcat acagaaggcg tcaattggtc   1440ccatcgaatt aggaggaaaa actgtttcat acagaaggcg tcaattagga ggaaaaactg   1500tttcatacag aaggcgtcaa ttaggaggaa aaactgtttc atacagaagg cgtcaattgg   1560tcccgggaca ttttgacacc cccataatat ttttccagaa ttaacagtat aaattgcatc   1620tcttgttcaa gagttcccta tcactctctt taatcactac tcacagtaac ctcaactcct   1680gtctagacca ccatggagtt tgggctgagc tgggttttcc tcgttgctct ttttagaggt   1740gtacagtgta tctgggagct gaagaaggac gtgtacgtgg tggagctgga ctggtacccc   1800gacgcccccg gcgagatggt ggtattaacc tgcgacaccc cagaggaaga cggcatcacc   1860tggaccctgg accagtcaag cgaggtgctg ggtagcggca agaccctgac catccaggtg   1920aaggagttcg gcgacgccgg ccagtacacc tgccacaagg gcggcgaggt gctgagccac   1980agcctactgc ttctccacaa gaaggaggac ggcatctgga gcaccgacat cctgaaggac   2040cagaaggagc ccaagaacaa gaccttcctg cgctgcgagg ccaagaatta ctcaggacga   2100ttcacctgct ggtggctgac caccatcagc accgacctga ccttcagcgt gaagagcagc   2160cgcggcagca gcgaccccca gggcgtgacc tgcggcgccg ccaccctgag cgccgagcgc   2220gtgcgcggcg acaacaagga gtacgagtac agcgtggagt gccaggagga cagcgcctgc   2280cccgccgccg aggagagcct gcccatcgag gtgatggtgg acgccgtgca caagctgaag   2340tacgagaact acaccagcag cttcttcatc cgcgacatca tcaagcccga cccacccaag   2400aacctgcagc tgaagcccct gaagaacagc cgccaggtgg aggtgagctg ggagtacccc   2460gacacctgga gcacccccca cagctacttc agcctgacct tctgcgtgca ggtgcagggc   2520aagagcaagc gcgagaagaa ggaccgcgtg ttcaccgaca agaccagcgc caccgtgatc   2580tgccgcaaga atgcgagcat cagcgtgcgc gcccaggacc gctactacag cagcagctgg   2640agcgagtggg ccagcgtgcc ctgcagcgga ggtggcggtg gaggcagccg caacctgccc   2700gtggccaccc ccgaccccgg catgttcccc tgcctgcacc acagccagaa cctgctgcgc   2760gccgtgagca acatgctgca gaaggcccgc cagaccctgg agttctaccc ctgcaccagc   2820gaggagatcg accacgagga catcaccaag gacaagacca gcaccgtgga ggcctgcctg   2880cccctggagc tgaccaagaa cgagagctgt ctgaacagca gagagactag cttcatcact   2940aacggcagct gcctagccag ccgcaagacc agcttcatga tggccctgtg cctgagcagc   3000atctacgagg acctgaagat gtaccaggtg gagttcaaga ccatgaacgc caagctgctg   3060atggacccca agcgccagat cttcctggac cagaacatgc tggccgtgat cgacgagctg   3120atgcaggccc tgaacttcaa cagcgagacc gtgccccaga agagcagcct ggaggagccc   3180gacttctaca agaccaagat caagctgtgc atcctgctgc acgccttccg catccgcgcc   3240gtgaccatcg accgcgtgat gagctacctg aacgcatcag ttaacggcag cggcgccacc   3300aacttcagcc tgctgaagca ggccggcgac gtggaggaga accccggccc ctctagagcc   3360accatggaca tgcgagttcc tgcccaactg cttggccttc ttttgctctg gctgccagga   3420gccaagtgcc aggtgcagct ggtggagagt ggaggtggcg tggtacagcc cggccgcagc   3480ctgcgcctgg actgcaaggc cagcggcatc accttcagca acagcggcat gcactgggtg   3540cgccaggccc ccggcaaggg cctggagtgg gtggccgtga tctggtacga cggcagcaag   3600cgctactacg ccgacagcgt gaagggccgc ttcaccatca gccgcgacaa cagcaagaac   3660accctgttcc tgcagatgaa cagcctgcgc gccgaggaca ccgccgtgta ctactgcgcc   3720accaacgacg actactgggg ccagggcacc ctggtgaccg tgagcagcgg tggcggtggc   3780tcgggcggtg gtgggtcggg tggcggcgga tctgagatcg tgctgaccca gagccccgcc   3840accctgagcc tgagccccgg cgagcgcgcc accctgagct gccgcgccag ccagagcgtg   3900agcagctacc tggcctggta ccagcagaag ccaggacagg ctccacgact gctaatctat   3960gacgccagca accgcgccac cggcatcccc gcccgcttca gcggcagcgg cagcggcacc   4020gacttcaccc tgaccatcag cagcctggag cccgaggact tcgccgtgta ctactgccag   4080cagagcagca actggccccg caccttcggc cagggcacca aggtggagat caag         4134</s400><s200><s210>52</s210><s211>726</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 52gatattcaga tgacacagac tactagctct ctgagcgcaa gtttgggcga ccgcgtcaca     60atctcttgtc gagctagtca agacattagt aagtacctga attggtacca acagaaacca    120gacggtacag tgaagctgct catttaccac acaagcagac tccacagcgg cgtgccttcc    180cggttcagtg gctccgggag cggtaccgat tatagcctta cgatctccaa cctcgaacag    240gaagacatcg ctacatactt ctgtcagcaa ggtaacaccc tcccctacac gttcggggga    300ggcacaaagt tggagattac cggaggcggc ggttctggtg gcggtgggag cggaggcggt    360gggagcgaag tcaaactcca ggaatcaggc cctggccttg tcgcccctag tcaaagtctg    420agcgttacgt gcactgtctc aggtgtttca cttcctgact atggggtatc atggataaga    480cagcctccac gaaaaggtct tgagtggctc ggagtcatat ggggtagtga gactacttac    540tataacagcg ccctgaaatc aagattgacc ataatcaaag ataatagtaa gagtcaggta    600tttttgaaaa tgaactcttt gcaaactgat gataccgcca tttattactg cgctaaacat    660tactattatg gcggttccta tgcgatggac tattggggcc aaggaacgtc cgtaacggtt    720tccagt                                                               726</s400><s200><s210>53</s210><s211>242</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 53Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly1               5                   10                  15Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr            20                  25                  30Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile        35                  40                  45Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln65                  70                  75                  80Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr                85                  90                  95Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr Gly Gly Gly Gly Ser            100                 105                 110Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Lys Leu Gln Glu        115                 120                 125Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser Val Thr Cys    130                 135                 140Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg145                 150                 155                 160Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Gly Ser                165                 170                 175Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser Arg Leu Thr Ile Ile            180                 185                 190Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln        195                 200                 205Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly    210                 215                 220Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val225                 230                 235                 240Ser Ser</s400><s200><s210>54</s210><s211>1395</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 54gacatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagagtcacc     60atcagttgca gggcaagtca ggacattagt aaatatttaa attggtatca gcagaaacca    120gatggaactg ttaaactcct gatctaccat acatcaagat tacactcagg agtcccatca    180aggttcagtg gcagtgggtc tggaacagat tattctctca ccattagcaa cctggagcaa    240gaagatattg ccacttactt ttgccaacag ggtaatacgc ttccgtacac gttcggaggg    300gggaccaagc tggagatcac aggtggcggt ggctcgggcg gtggtgggtc gggtggcggc    360ggatctgagg tgaaactgca ggagtcagga cctggcctgg tggcgccctc acagagcctg    420tccgtcacat gcactgtctc aggggtctca ttacccgact atggtgtaag ctggattcgc    480cagcctccac gaaagggtct ggagtggctg ggagtaatat ggggtagtga aaccacatac    540tataattcag ctctcaaatc cagactgacc atcatcaagg acaactccaa gagccaagtt    600ttcttaaaaa tgaacagtct gcaaactgat gacacagcca tttactactg tgccaaacat    660tattactacg gtggtagcta tgctatggac tactggggcc aaggaacctc agtcaccgtc    720tcctcaacca cgacgccagc gccgcgacca ccaacaccgg cgcccaccat cgcgtcgcag    780cccctgtccc tgcgcccaga ggcgtgccgg ccagcggcgg ggggcgcagt gcacacgagg    840gggctggact tcgcctgtga tatctacatc tgggcgccct tggccgggac ttgtggggtc    900cttctcctgt cactggttat caccctttac tgcaaacggg gcagaaagaa actcctgtat    960atattcaaac aaccatttat gagaccagta caaactactc aagaggaaga tggctgtagc   1020tgccgatttc cagaagaaga agaaggagga tgtgaactga gagtgaagtt cagcaggagc   1080gcagacgccc ccgcgtacaa gcagggccag aaccagctct ataacgagct caatctagga   1140cgaagagagg agtacgatgt tttggacaag agacgtggcc gggaccctga gatgggggga   1200aagccgagaa ggaagaaccc tcaggaaggc ctgtacaatg aactgcagaa agataagatg   1260gcggaggcct acagtgagat tgggatgaaa ggcgagcgcc ggaggggcaa ggggcacgat   1320ggcctttacc agggtctcag tacagccacc aaggacacct acgacgccct tcacatgcag   1380gccctgcccc ctcgc                                                    1395</s400><s200><s210>55</s210><s211>465</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 55Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly1               5                   10                  15Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr            20                  25                  30Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile        35                  40                  45Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln65                  70                  75                  80Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr                85                  90                  95Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr Gly Gly Gly Gly Ser            100                 105                 110Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Lys Leu Gln Glu        115                 120                 125Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser Val Thr Cys    130                 135                 140Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg145                 150                 155                 160Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Gly Ser                165                 170                 175Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser Arg Leu Thr Ile Ile            180                 185                 190Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln        195                 200                 205Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly    210                 215                 220Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val225                 230                 235                 240Ser Ser Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr                245                 250                 255Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala            260                 265                 270Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile        275                 280                 285Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser    290                 295                 300Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr305                 310                 315                 320Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu                325                 330                 335Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu            340                 345                 350Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln        355                 360                 365Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu    370                 375                 380Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly385                 390                 395                 400Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln                405                 410                 415Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu            420                 425                 430Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr        435                 440                 445Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro    450                 455                 460Arg465</s400><s200><s210>56</s210><s211>714</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 56gaggtgcagc tggtggagag cggaggcggt ctggtgcagc ccggaggtag cctacgtctg     60agctgcgctg caagcggcta ctcaatcacc aacgactacg cctggaactg ggtgcgccag    120gcacctggca agggcctgga gtgggtgggc tacatcagct acagcggcta caccacctac    180aaccccagcc tgaagagccg cttcaccatc agccgcgaca ccagcaagaa caccctgtac    240ctgcagatga acagcctgcg cgccgaggac accgccgtgt actactgcgc tcgctggact    300agcggtctgg actactgggg acagggtact ctggtgaccg tgagcagcgg tggcggtggc    360tcgggaggtg gagggtcggg tggcggcgga tctgacatcc agatgaccca gagccccagc    420agcctgagcg ccagcgtggg cgaccgcgtg accatcacct gcaaggccag cgacctgatc    480cacaactggc tggcctggta ccagcagaag cccggcaagg cccccaagct gctgatctac    540ggcgccacca gcctggagac cggcgtgccc agccgcttca gcggcagcgg cagcggcacc    600gacttcaccc tgaccatcag cagcctgcag cccgaggact tcgccaccta ctactgccag    660cagtactgga ccaccccctt caccttcggc cagggcacca aggtggagat caag          714</s400><s200><s210>57</s210><s211>238</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 57Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser Ile Thr Asn Asp            20                  25                  30Tyr Ala Trp Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp        35                  40                  45Val Gly Tyr Ile Ser Tyr Ser Gly Tyr Thr Thr Tyr Asn Pro Ser Leu    50                  55                  60Lys Ser Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr Leu Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Trp Thr Ser Gly Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val            100                 105                 110Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly        115                 120                 125Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala    130                 135                 140Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Asp Leu Ile145                 150                 155                 160His Asn Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys                165                 170                 175Leu Leu Ile Tyr Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg            180                 185                 190Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser        195                 200                 205Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Thr    210                 215                 220Thr Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys225                 230                 235</s400><s200><s210>58</s210><s211>756</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 58gacattgtta tgacgcagag ccctgattcc ctcgccgtgt cactgggcga gagggcgact     60atcaactgta aaagcagcca atcactgctc tatagccgaa accagaaaaa ctacctcgcg    120tggtaccaac agaaaccagg gcagccacct aagctgctca ttttttgggc aagtacgcgc    180gaatctggcg tgcctgacag gttttctggg agtggttttg gcaccgattt tacattgaca    240atttccagct tgcaagcaga agatgtcgct gtgtactatt gtcaacagta cttcagctat    300cctcttacgt ttgggcaagg aaccaaggtg gagatcaaag gtggcggtgg ctcgggcggt    360ggtgggtcgg gtggcggcgg atctcaggtc cagctcgtcc agtccggggc tgaggttaag    420aagccgggtg cttctgtgaa agtgtcatgc aaaacgagcc gatatacctt tacggaatat    480acgatacact gggtgaggca agcgccgggt cagaggttgg aatggatcgg tgggatcaac    540cctaataatg ggatacctaa ctataatcag aaatttaaag gccgggttac tattaccgtg    600gatacgtccg cgtcaacagc ctacatggaa ctctcctcac tcaggagcga agatactgcg    660gtgtattact gtgcccgccg ccgcattgcg tatggatacg atgaagggca cgcgatggac    720tactggggac aaggtacact tgtgacggtc tcatca                              756</s400><s200><s210>59</s210><s211>252</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 59Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser            20                  25                  30Arg Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Phe Trp Ala Ser Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Phe Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln                85                  90                  95Tyr Phe Ser Tyr Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser        115                 120                 125Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala    130                 135                 140Ser Val Lys Val Ser Cys Lys Thr Ser Arg Tyr Thr Phe Thr Glu Tyr145                 150                 155                 160Thr Ile His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile                165                 170                 175Gly Gly Ile Asn Pro Asn Asn Gly Ile Pro Asn Tyr Asn Gln Lys Phe            180                 185                 190Lys Gly Arg Val Thr Ile Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr        195                 200                 205Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys    210                 215                 220Ala Arg Arg Arg Ile Ala Tyr Gly Tyr Asp Glu Gly His Ala Met Asp225                 230                 235                 240Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser                245                 250</s400><s200><s210>60</s210><s211>111</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 60cggagggacc agaggctgcc ccccgatgcc cacaagcccc ctgggggagg cagtttccgg     60acccccatcc aagaggagca ggccgacgcc cactccaccc tggccaagat c             111</s400><s200><s210>61</s210><s211>37</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 61Arg Arg Asp Gln Arg Leu Pro Pro Asp Ala His Lys Pro Pro Gly Gly1               5                   10                  15Gly Ser Phe Arg Thr Pro Ile Gln Glu Glu Gln Ala Asp Ala His Ser            20                  25                  30Thr Leu Ala Lys Ile        35</s400><s200><s210>62</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 62Asn Ser Gly Met His1               5</s400><s200><s210>63</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 63Val Ile Trp Tyr Asp Gly Ser Lys Arg Tyr Tyr Ala Asp Ser Val Lys1               5                   10                  15Gly</s400><s200><s210>64</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 64Asn Asp Asp Tyr1</s400><s200><s210>65</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 65Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala1               5                   10</s400><s200><s210>66</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 66Asp Ala Ser Asn Arg Ala Thr1               5</s400><s200><s210>67</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 67Gln Gln Ser Ser Asn Trp Pro Arg Thr1               5</s400><s200><s210>68</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 68Asp Ser Trp Ile His1               5</s400><s200><s210>69</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 69Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys1               5                   10                  15Gly</s400><s200><s210>70</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 70Arg His Trp Pro Gly Gly Phe Asp Tyr1               5</s400><s200><s210>71</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 71Arg Ala Ser Gln Asp Val Ser Thr Ala Val Ala1               5                   10</s400><s200><s210>72</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 72Ser Ala Ser Phe Leu Tyr Ser1               5</s400><s200><s210>73</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 73Gln Gln Tyr Leu Tyr His Pro Ala Thr1               5</s400><s200><s210>74</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 74Glu Tyr Thr Ile His1               5</s400><s200><s210>75</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 75Asn Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe Glu1               5                   10                  15Asp</s400><s200><s210>76</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 76Gly Trp Asn Phe Asp Tyr1               5</s400><s200><s210>77</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 77Lys Ala Ser Gln Asp Val Gly Thr Ala Val Asp1               5                   10</s400><s200><s210>78</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 78Trp Ala Ser Thr Arg His Thr1               5</s400><s200><s210>79</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 79Gln Gln Tyr Asn Ser Tyr Pro Leu Thr1               5</s400><s200><s210>80</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 80Asp Tyr Glu Met His1               5</s400><s200><s210>81</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 81Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe Lys1               5                   10                  15Gly</s400><s200><s210>82</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 82Phe Tyr Ser Tyr Thr Tyr1               5</s400><s200><s210>83</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 83Arg Ser Ser Gln Ser Leu Val His Ser Asn Arg Asn Thr Tyr Leu His1               5                   10                  15</s400><s200><s210>84</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 84Lys Val Ser Asn Arg Phe Ser1               5</s400><s200><s210>85</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 85Ser Gln Asn Thr His Val Pro Pro Thr1               5</s400><s200><s210>86</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 86Asp Tyr Gly Val Ser1               5</s400><s200><s210>87</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 87Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser1               5                   10                  15</s400><s200><s210>88</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 88His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr1               5                   10</s400><s200><s210>89</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 89Arg Ala Ser Gln Asp Ile Ser Lys Tyr Leu Asn1               5                   10</s400><s200><s210>90</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 90His Thr Ser Arg Leu His Ser1               5</s400><s200><s210>91</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 91Gln Gln Gly Asn Thr Leu Pro Tyr Thr1               5</s400><s200><s210>92</s210><s211>18</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 92Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu Glu Asn Pro1               5                   10                  15Gly Pro</s400><s200><s210>93</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 93Asn Asp Tyr Ala Trp Asn1               5</s400><s200><s210>94</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 94Tyr Ile Ser Tyr Ser Gly Tyr Thr Thr Tyr Asn Pro Ser Leu Lys Ser1               5                   10                  15</s400><s200><s210>95</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 95Trp Thr Ser Gly Leu Asp Tyr1               5</s400><s200><s210>96</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 96Lys Ala Ser Asp Leu Ile His Asn Trp Leu Ala1               5                   10</s400><s200><s210>97</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 97Gly Ala Thr Ser Leu Glu Thr1               5</s400><s200><s210>98</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 98Gln Gln Tyr Trp Thr Thr Pro Phe Thr1               5</s400><s200><s210>99</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 99Glu Tyr Thr Ile His1               5</s400><s200><s210>100</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 100Gly Ile Asn Pro Asn Asn Gly Ile Pro Asn Tyr Asn Gln Lys Phe Lys1               5                   10                  15Gly</s400><s200><s210>101</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 101Arg Arg Ile Ala Tyr Gly Tyr Asp Glu Gly His Ala Met Asp Tyr1               5                   10                  15</s400><s200><s210>102</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 102Lys Ser Ser Gln Ser Leu Leu Tyr Ser Arg Asn Gln Lys Asn Tyr Leu1               5                   10                  15Ala</s400><s200><s210>103</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 103Trp Ala Ser Thr Arg Glu Ser1               5</s400><s200><s210>104</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 104Gln Gln Tyr Phe Ser Tyr Pro Leu Thr1               5</s400><s200><s210>105</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 105Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr            20                  25                  30Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met        35                  40                  45Gly Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe    50                  55                  60Lys Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Thr Arg Phe Tyr Ser Tyr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>106</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 106Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly1               5                   10                  15Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser            20                  25                  30Asn Arg Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser        35                  40                  45Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro    50                  55                  60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65                  70                  75                  80Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Asn                85                  90                  95Thr His Val Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys            100                 105                 110</s400><s200><s210>107</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 107Glu Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Thr Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr            20                  25                  30Thr Ile His Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile        35                  40                  45Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe    50                  55                  60Glu Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Thr Asp Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Ala Gly Trp Asn Phe Asp Tyr Trp Gly Gln Gly Thr Leu Leu Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>108</s210><s211>107</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 108Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Thr Ser Val Gly1               5                   10                  15Asp Arg Val Thr Leu Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala            20                  25                  30Val Asp Trp Tyr Gln Gln Lys Pro Gly Pro Ser Pro Lys Leu Leu Ile        35                  40                  45Tyr Trp Ala Ser Thr Arg His Thr Gly Ile Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Glu Asp Phe Ala Asp Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Leu                85                  90                  95Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys            100                 105</s400><s200><s210>109</s210><s211>113</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 109Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Asp Cys Lys Ala Ser Gly Ile Thr Phe Ser Asn Ser            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Val Ile Trp Tyr Asp Gly Ser Lys Arg Tyr Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Thr Asn Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser            100                 105                 110Ser</s400><s200><s210>110</s210><s211>107</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 110Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Ser Asn Trp Pro Arg                85                  90                  95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>111</s210><s211>118</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 111Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ser            20                  25                  30Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Arg His Trp Pro Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr            100                 105                 110Leu Val Thr Val Ser Ser        115</s400><s200><s210>112</s210><s211>107</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 112Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Thr Ala            20                  25                  30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Leu Tyr His Pro Ala                85                  90                  95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>113</s210><s211>120</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 113Glu Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln1               5                   10                  15Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr            20                  25                  30Gly Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu        35                  40                  45Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys    50                  55                  60Ser Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu65                  70                  75                  80Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala                85                  90                  95Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln            100                 105                 110Gly Thr Ser Val Thr Val Ser Ser        115                 120</s400><s200><s210>114</s210><s211>107</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 114Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly1               5                   10                  15Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr            20                  25                  30Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile        35                  40                  45Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln65                  70                  75                  80Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr                85                  90                  95Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr            100                 105</s400><s200><s210>115</s210><s211>116</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 115Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser Ile Thr Asn Asp            20                  25                  30Tyr Ala Trp Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp        35                  40                  45Val Gly Tyr Ile Ser Tyr Ser Gly Tyr Thr Thr Tyr Asn Pro Ser Leu    50                  55                  60Lys Ser Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr Leu Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Trp Thr Ser Gly Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val            100                 105                 110Thr Val Ser Ser        115</s400><s200><s210>116</s210><s211>107</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 116Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Asp Leu Ile His Asn Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Thr Thr Pro Phe                85                  90                  95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>117</s210><s211>124</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 117Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Thr Ser Arg Tyr Thr Phe Thr Glu Tyr            20                  25                  30Thr Ile His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Gly Ile Asn Pro Asn Asn Gly Ile Pro Asn Tyr Asn Gln Lys Phe    50                  55                  60Lys Gly Arg Val Thr Ile Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Arg Arg Ile Ala Tyr Gly Tyr Asp Glu Gly His Ala Met Asp            100                 105                 110Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser        115                 120</s400><s200><s210>118</s210><s211>113</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 118Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser            20                  25                  30Arg Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Phe Trp Ala Ser Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Phe Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln                85                  90                  95Tyr Phe Ser Tyr Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys</s400><s200><s210>119</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 119Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu1               5                   10                  15Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Val Ser Ser Gly            20                  25                  30Asp Tyr Tyr Trp Thr Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu        35                  40                  45Trp Ile Gly His Ile Tyr Tyr Ser Gly Asn Thr Asn Tyr Asn Pro Ser    50                  55                  60Leu Lys Ser Arg Leu Thr Ile Ser Ile Asp Thr Ser Lys Thr Gln Phe65                  70                  75                  80Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Ile Tyr Tyr                85                  90                  95Cys Val Arg Asp Arg Val Thr Gly Ala Phe Asp Ile Trp Gly Gln Gly            100                 105                 110Thr Met Val Thr Val Ser Ser        115</s400><s200><s210>120</s210><s211>107</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 120Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr            20                  25                  30Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Glu Asp Ile Ala Thr Tyr Phe Cys Gln His Phe Asp His Leu Pro Leu                85                  90                  95Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>121</s210><s211>120</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 121Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr            20                  25                  30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln            100                 105                 110Gly Thr Leu Val Thr Val Ser Ser        115                 120</s400><s200><s210>122</s210><s211>107</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 122Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala            20                  25                  30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro                85                  90                  95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>123</s210><s211>122</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 123Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala1               5                   10                  15Ser Met Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr            20                  25                  30Thr Met Asn Trp Val Lys Gln Ser His Gly Lys Asn Leu Glu Trp Met        35                  40                  45Gly Leu Ile Asn Pro Tyr Lys Gly Val Ser Thr Tyr Asn Gln Lys Phe    50                  55                  60Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Leu Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Ser Gly Tyr Tyr Gly Asp Ser Asp Trp Tyr Phe Asp Val Trp            100                 105                 110Gly Gln Gly Thr Thr Leu Thr Val Phe Ser        115                 120</s400><s200><s210>124</s210><s211>107</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 124Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly1               5                   10                  15Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Arg Asn Tyr            20                  25                  30Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile        35                  40                  45Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Lys Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln65                  70                  75                  80Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp                85                  90                  95Thr Phe Ala Gly Gly Thr Lys Leu Glu Ile Lys            100                 105</s400><s200><s210>125</s210><s211>528</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 125Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu1               5                   10                  15His Ala Ala Arg Pro Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu            20                  25                  30Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln        35                  40                  45Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr    50                  55                  60Val Lys Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Val Pro65                  70                  75                  80Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile                85                  90                  95Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly            100                 105                 110Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr        115                 120                 125Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu    130                 135                 140Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser145                 150                 155                 160Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly                165                 170                 175Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly            180                 185                 190Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser        195                 200                 205Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys    210                 215                 220Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys225                 230                 235                 240His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly                245                 250                 255Thr Ser Val Thr Val Ser Ser Gly Gly Gly Glu Ala Ala Ala Lys Glu            260                 265                 270Ala Ala Ala Lys Glu Ala Ala Ala Lys Ala Gly Gly Glu Val Gln Leu        275                 280                 285Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Met Lys Ile    290                 295                 300Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Thr Met Asn Trp305                 310                 315                 320Val Lys Gln Ser His Gly Lys Asn Leu Glu Trp Met Gly Leu Ile Asn                325                 330                 335Pro Tyr Lys Gly Val Ser Thr Tyr Asn Gln Lys Phe Lys Asp Lys Ala            340                 345                 350Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Leu        355                 360                 365Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ser Gly    370                 375                 380Tyr Tyr Gly Asp Ser Asp Trp Tyr Phe Asp Val Trp Gly Gln Gly Thr385                 390                 395                 400Thr Leu Thr Val Phe Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                405                 410                 415Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu            420                 425                 430Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln        435                 440                 445Asp Ile Arg Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr    450                 455                 460Val Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro465                 470                 475                 480Ser Lys Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile                485                 490                 495Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly            500                 505                 510Asn Thr Leu Pro Trp Thr Phe Ala Gly Gly Thr Lys Leu Glu Ile Lys        515                 520                 525</s400><s200><s210>126</s210><s211>507</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 126Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala            20                  25                  30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro                85                  90                  95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser            100                 105                 110Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu        115                 120                 125Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys    130                 135                 140Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr Ile His Trp Val Arg145                 150                 155                 160Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Tyr Pro Thr                165                 170                 175Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile            180                 185                 190Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu        195                 200                 205Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp    210                 215                 220Gly Phe Tyr Ala Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val225                 230                 235                 240Ser Ser Gly Gly Gly Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu                245                 250                 255Ala Ala Ala Lys Ala Gly Gly Glu Val Gln Leu Gln Gln Ser Gly Pro            260                 265                 270Glu Leu Val Lys Pro Gly Ala Ser Met Lys Ile Ser Cys Lys Ala Ser        275                 280                 285Gly Tyr Ser Phe Thr Gly Tyr Thr Met Asn Trp Val Lys Gln Ser His    290                 295                 300Gly Lys Asn Leu Glu Trp Met Gly Leu Ile Asn Pro Tyr Lys Gly Val305                 310                 315                 320Ser Thr Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Val Asp                325                 330                 335Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Leu Ser Leu Thr Ser Glu            340                 345                 350Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ser Gly Tyr Tyr Gly Asp Ser        355                 360                 365Asp Trp Tyr Phe Asp Val Trp Gly Gln Gly Thr Thr Leu Thr Val Phe    370                 375                 380Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser385                 390                 395                 400Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly                405                 410                 415Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Arg Asn Tyr            420                 425                 430Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile        435                 440                 445Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Lys Phe Ser Gly    450                 455                 460Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln465                 470                 475                 480Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp                485                 490                 495Thr Phe Ala Gly Gly Thr Lys Leu Glu Ile Lys            500                 505</s400><s200><s210>127</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 127Gly Tyr Thr Met Asn1               5</s400><s200><s210>128</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 128Leu Ile Asn Pro Tyr Lys Gly Val Ser Thr Tyr Asn Gln Lys Phe Lys1               5                   10                  15Asp</s400><s200><s210>129</s210><s211>13</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 129Ser Gly Tyr Tyr Gly Asp Ser Asp Trp Tyr Phe Asp Val1               5                   10</s400><s200><s210>130</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 130Arg Ala Ser Gln Asp Ile Arg Asn Tyr Leu Asn1               5                   10</s400><s200><s210>131</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 131Tyr Thr Ser Arg Leu His Ser1               5</s400><s200><s210>132</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 132Gln Gln Gly Asn Thr Leu Pro Trp Thr1               5</s400><s200><s210>133</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 133Ser Gly Asp Tyr Tyr Trp Thr1               5</s400><s200><s210>134</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 134His Ile Tyr Tyr Ser Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys Ser1               5                   10                  15</s400><s200><s210>135</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 135Asp Arg Val Thr Gly Ala Phe Asp Ile1               5</s400><s200><s210>136</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 136Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn1               5                   10</s400><s200><s210>137</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 137Asp Ala Ser Asn Leu Glu Thr1               5</s400><s200><s210>138</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 138Gln His Phe Asp His Leu Pro Leu Ala1               5</s400><s200><s210>139</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 139Asp Thr Tyr Ile His1               5</s400><s200><s210>140</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 140Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys1               5                   10                  15Gly</s400><s200><s210>141</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 141Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr1               5                   10</s400><s200><s210>142</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 142Arg Ala Ser Gln Asp Val Asn Thr Ala Val Ala1               5                   10</s400><s200><s210>143</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 143Ser Ala Ser Phe Leu Tyr Ser1               5</s400><s200><s210>144</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 144Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr1               5                   10</s400><s200><s210>145</s210><s211>129</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 145agtaagagga gcaggctcct gcacagtgac tacatgaaca tgactccccg ccgccccggg     60cccacccgca agcattacca gccctatgcc ccaccacgcg acttcgcagc ctatcgctcc    120ggcggaggg                                                            129</s400><s200><s210>146</s210><s211>43</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 146Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro1               5                   10                  15Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro            20                  25                  30Arg Asp Phe Ala Ala Tyr Arg Ser Gly Gly Gly        35                  40</s400><s200><s210>147</s210><s211>162</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 147cacctttgga gaagacagtg gcgaccaaga cgattttctg ccttagagca agggattcac     60cctccgcagg ctcagagcaa gatagaggag ctggagcaag aaccggagcc ggagccggag    120ccggaaccgg agcccgagcc cgagcccgag ccggagcagc tc                       162</s400><s200><s210>148</s210><s211>54</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 148His Leu Trp Arg Arg Gln Trp Arg Pro Arg Arg Phe Ser Ala Leu Glu1               5                   10                  15Gln Gly Ile His Pro Pro Gln Ala Gln Ser Lys Ile Glu Glu Leu Glu            20                  25                  30Gln Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu        35                  40                  45Pro Glu Pro Glu Gln Leu    50</s400><s200><s210>149</s210><s211>10</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 149gggaatttcc                                                            10</s400><s200><s210>150</s210><s211>11</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 150ggggactttc c                                                          11</s400><s200><s210>151</s210><s211>52</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 151gggaatttcc ggggactttc cgggaatttc cggggacttt ccgggaattt cc             52</s400><s200><s210>152</s210><s211>68</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 152ggggactttc cgcttgggga ctttccgctg gggactttcc gctggggact ttccgctggg     60gactttcc                                                              68</s400><s200><s210>153</s210><s211>32</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 153tagagggtat ataatggaag ctcgacttcc ag                                   32</s400><s200><s210>154</s210><s211>46</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 154gggtcgaggt aggcgtgtac ggtgggaggc ctatataagc agagct                    46</s400><s200><s210>155</s210><s211>182</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 155agcttgaata aaatgaatat tagaagctgt tagaataaga gaaaatgaca gaggaaaact     60gaaagggaga actgaaagtg ggaaattcct ctgaggcaga aaggaccatc ccttataaat    120agcacaggcc atgaaggaag atcattctca ctgcagcctt tgacagcctt tgcctcatct    180tg                                                                   182</s400><s200><s210>156</s210><s211>256</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>artificially synthesized</s223></s220></s200><s400> 156ggggactttc cgcttgggga ctttccgctg gggactttcc gctggggact ttccgctggg     60gactttccga attcagcttg aataaaatga atattagaag ctgttagaat aagagaaaat    120gacagaggaa aactgaaagg gagaactgaa agtgggaaat tcctctgagg cagaaaggac    180catcccttat aaatagcaca ggccatgaag gaagatcatt ctcactgcag cctttgacag    240cctttgcctc atcttg                                                    256</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230000919A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230000919</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17864546</doc-number><date>20220714</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>35</main-group><subgroup>17</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>P</subclass><main-group>35</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>5</main-group><subgroup>0783</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>5</main-group><subgroup>077</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>35</main-group><subgroup>17</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20180101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>P</subclass><main-group>35</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>5</main-group><subgroup>0636</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>5</main-group><subgroup>0669</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>2035</main-group><subgroup>124</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">ACTIVATION OF MARROW INFILTRATING LYMPHOCYTES IN HYPOXIC ALTERNATING WITH NORMOXIC CONDITIONS</invention-title><us-related-documents><continuation><relation><parent-doc><document-id><country>US</country><doc-number>16526656</doc-number><date>20190730</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>11406666</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>17864546</doc-number></document-id></child-doc></relation></continuation><continuation><relation><parent-doc><document-id><country>US</country><doc-number>15606766</doc-number><date>20170526</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>10406178</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>16526656</doc-number></document-id></child-doc></relation></continuation><continuation><relation><parent-doc><document-id><country>US</country><doc-number>15112353</doc-number><date>20160718</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>9687510</doc-number></document-id></parent-grant-document><parent-pct-document><document-id><country>WO</country><doc-number>PCT/US2015/048536</doc-number><date>20150904</date></document-id></parent-pct-document></parent-doc><child-doc><document-id><country>US</country><doc-number>15606766</doc-number></document-id></child-doc></relation></continuation><us-provisional-application><document-id><country>US</country><doc-number>62186040</doc-number><date>20150629</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>62045782</doc-number><date>20140904</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>The Johns Hopkins University</orgname><address><city>Baltimore</city><state>MD</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Borrello</last-name><first-name>Ivan M.</first-name><address><city>Baltimore</city><state>MD</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Noonan</last-name><first-name>Kimberly A.</first-name><address><city>Baltimore</city><state>MD</state><country>US</country></address></addressbook></inventor></inventors></us-parties></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">In some aspects, the invention relates to compositions comprising marrow infiltrating lymphocytes (&#x201c;MILs&#x201d;). The MILs may be activated MILs. In some aspects, the invention relates to methods for activating MILs, comprising incubating MILs in an environment comprising less than 21% oxygen. In some aspects, the invention relates to methods for treating cancer in a subject, comprising administering to the subject a composition comprising activated MILs.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="204.55mm" wi="165.61mm" orientation="landscape" file="US20230000919A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="171.53mm" wi="142.66mm" orientation="landscape" file="US20230000919A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="185.50mm" wi="143.59mm" orientation="landscape" file="US20230000919A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="178.14mm" wi="146.13mm" orientation="landscape" file="US20230000919A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="229.70mm" wi="101.52mm" orientation="landscape" file="US20230000919A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="181.61mm" wi="129.54mm" orientation="landscape" file="US20230000919A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="215.05mm" wi="157.56mm" orientation="landscape" file="US20230000919A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="219.79mm" wi="160.78mm" orientation="landscape" file="US20230000919A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="219.29mm" wi="163.75mm" orientation="landscape" file="US20230000919A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00010" num="00010"><img id="EMI-D00010" he="214.04mm" wi="157.31mm" orientation="landscape" file="US20230000919A1-20230105-D00010.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00011" num="00011"><img id="EMI-D00011" he="205.06mm" wi="159.94mm" orientation="landscape" file="US20230000919A1-20230105-D00011.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00012" num="00012"><img id="EMI-D00012" he="182.03mm" wi="159.94mm" orientation="landscape" file="US20230000919A1-20230105-D00012.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00013" num="00013"><img id="EMI-D00013" he="230.63mm" wi="164.42mm" orientation="landscape" file="US20230000919A1-20230105-D00013.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?><heading id="h-0001" level="1">PRIORITY CLAIM</heading><p id="p-0002" num="0001">This application claims priority to U.S. Provisional Patent Application No. 62/045,782, filed on Sep. 4, 2014, and U.S. Provisional Patent Application No. 62/186,040, filed on Jun. 29, 2015, each of which is hereby incorporated by reference in its entirety.</p><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0002" level="1">BACKGROUND</heading><p id="p-0003" num="0002">Myeloablative chemotherapy is an accepted therapy for many hematologic malignancies including multiple myeloma albeit with minimal evidence of long-term cures. However, the myeloablative therapy also provides an ideal platform for the superimposition of immune-based therapies. Specifically, the lymphopenia resulting from high dose chemotherapy facilitates homeostatic lymphocytic proliferation, eliminates tolerogenic antigen presenting cells (APCs), and induces cytokine release that generates a more favorable environment for adoptive T cell therapy. Indirect evidence that the immune system can contribute to the clinical benefits of high dose chemotherapy was shown with early lymphoid recovery resulting in improved clinical outcomes in patients with myeloma, lymphoma, and acute myeloid leukemia undergoing an autologous stem cell transplant. Furthermore, these improved outcomes in myeloma correlated directly with the dose of autologous lymphocytes infused from the apheresis product. Taken together, these data support the hypothesis that anti-tumor immunity can have clinically measurable benefits and advances the question of how to harness such immunity to augment the efficacy of currently available therapies.</p><p id="p-0004" num="0003">The ability to eradicate measurable disease with adoptive T cell therapy (ACT) requires T cells to be appropriately activated and present in sufficient numbers, possess appreciable anti-tumor activity, home to the tumor site, effectively kill the tumor upon encounter, and persist over time. Stimulation of T cells with any technique including paramagnetic beads to which anti-CD3 and CD28 are bound can effectively reverse an anergic (tolerant) state, generate activated T cells, and significantly expand their numbers. While bead-bound anti-CD3 and CD28 provide a straightforward and robust T cell amplification in vitro, a major limitation of this approach is the non-specific stimulation of the entire T cell repertoire without enrichment of tumor specific T cells. One strategy to augment the tumor specificity of ACT is to use a T cell population with greater endogenous tumor specificity. Such an enrichment accounts for the considerable anti-tumor activity of ACT using tumor infiltrating lymphocytes (TILs) from metastatic melanoma. However, TILs are present only in a subset of patients with metastatic melanoma, and of those, successful TIL preparations can be achieved in only 60-70% of patients with harvestable tumor, which limits the general applicability of such an approach. Bone marrow is the tumor microenvironment for many hematologic malignancies such as multiple myeloma, and thus, marrow-infiltrating lymphocytes (MILs) could be harnessed to generate tumor specific T cell therapy for these specific cancers. In contrast to TILs, MILs are present in all patients, can be obtained with a simple bed-side procedure, and can be rapidly expanded in all patients.</p><p id="p-0005" num="0004">In hematologic malignancies, the bone marrow represents not only the site of disease but also a unique microenvironment. Even in solid tumors, evidence exists that MILs can be enriched in memory or effector-memory T cells. The immune component within the bone marrow is a reservoir of antigen experienced T cells for both tumor specific T cells in host with early stage breast cancer as well as vaccine-primed T cells. In the bone marrow, memory CD4 cells are maintained through interactions with IL-7 expressing stromal cells and CD8 cells are maintained through the persistence of antigen expression and effective antigen presentation. As such, the heightened tumor specificity of MILs in this setting is likely due to the presence of tumor as a source of antigen while their persistence is maintained through the unique immune interactions with stromal elements, cytokines, and antigen presenting cells capable of effective antigen presentation in this environment.</p><p id="p-0006" num="0005">Ex-vivo activated MILs possess several essential properties for adoptive T cell therapy. Upon activation, they demonstrate significant tumor specificity compared to their peripheral blood lymphocyte counterparts, and they target a broad range of antigens present on both the mature multiple myeloma plasma cells as well as their clonogenic precursors and effectively kill multiple myeloma plasma cells. Similar to TILs, MILs have a greater endogenous polyclonal antigenic specificity than peripheral lymphocytes. In contrast to TILs, MILs are present in all patients and are obtained from a more immune responsive microenvironment. As such, MILs represent a novel and promising tumor-specific approach to ACT for hematologic malignancies with bone marrow involvement.</p><heading id="h-0003" level="1">SUMMARY</heading><p id="p-0007" num="0006">In some aspects, the invention relates to a composition comprising marrow infiltrating lymphocytes (&#x201c;MILs&#x201d;). The composition may comprise a population of MILs that expresses CD3. For example, at least about 40% of the cells in the composition may be MILs from the population of MILs that expresses CD3. For example, the composition may comprise MILs, and 40% of the cells may express CD3 as determined by a flow cytometry gate; thus, at least about 40% of the cells in the composition would be from the population of MILs that expresses CD3. The composition may comprise a population of MILs that expresses interferon gamma (&#x201c;IFN&#x3b3;&#x201d;). For example, at least about 2% of the cells in the composition may be MILs from the population of MILs that expresses IFN&#x3b3;. The composition may comprise a population of MILs that expresses CXCR4. For example, at least about 98% of the cells in the composition may be MILs from the population of MILs that expresses CXCR4. The composition may comprise a population of MILs that expresses CD4. The composition may comprise a population of MILs that expresses CD8. The composition may comprise a population of MILs that expresses 4-1BB. For example, at least about 21% of the cells in the composition may be MILs from the population of MILs that expresses 4-1BB.</p><p id="p-0008" num="0007">In some aspects, the invention relates to a method for activating marrow infiltrating lymphocytes (&#x201c;MILs&#x201d;), comprising incubating MILs in an environment comprising less than 21% oxygen.</p><p id="p-0009" num="0008">In some aspects, the invention relates to a method for treating cancer in a subject. The method may comprise administering to the subject a composition comprising MILs. In some embodiments, the method comprises removing marrow infiltrating lymphocytes (&#x201c;MILs&#x201d;) from the subject; and incubating the MILs in an environment comprising less than 21% oxygen, thereby producing activated MILs.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0004" level="1">BRIEF DESCRIPTION OF THE FIGURES</heading><p id="p-0010" num="0009"><figref idref="DRAWINGS">FIG. <b>1</b></figref> depicts flow cytometry results for MILs that were expanded under either normoxic conditions or hypoxic conditions in media comprising interleukin 2 (+IL2) or media without interleukin 2 (No IL2). 35.09% of the gated cells grown under normoxic conditions in media comprising interleukin 2 were positive for CD3. 30.98% of the gated cells grown under normoxic conditions in media lacking interleukin 2 were positive for CD3. 89.01% of the gated cells grown under hypoxic conditions in media comprising interleukin 2 were positive for CD3. 89.96% of the gated cells grown under hypoxic conditions in media lacking interleukin 2 were positive for CD3.</p><p id="p-0011" num="0010"><figref idref="DRAWINGS">FIG. <b>2</b></figref> is a chart showing the expansion of CD3<sup>+</sup> cells for peripheral blood lymphocytes (PBLs) and MILs grown under normoxic or hypoxic conditions. Hypoxic conditions decreased the expansion of CD3<sup>+</sup> PBLs but increased the expansion of CD3<sup>+</sup> MILs.</p><p id="p-0012" num="0011"><figref idref="DRAWINGS">FIG. <b>3</b></figref> is a graph comparing the expansion of CD3<sup>+</sup> MILs after various time periods of incubation in either normoxic or hypoxic environments. Substantial expansion was observed after 7 days of incubation in a hypoxic environment compared to normoxia, and a CD3<sup>+</sup> expansion peaked at 11 days of incubation.</p><p id="p-0013" num="0012"><figref idref="DRAWINGS">FIG. <b>4</b></figref> is a graph depicting the tumor specificity of MILs expanded under hypoxic or normoxic conditions for either myeloma cell lines (U266/H929) or a control cell line (SW780), for cells that were expanded for either 10 days (D10) or for 12 days (D12). Hypoxic cells were grown for 3 days in an environment comprising 2% oxygen, followed by expansion in a normoxic environment (21% oxygen). On day 10, 4% of the cells expanded under normoxic conditions were tumor specific as compared to 25.1% of MILs expanded under hypoxic conditions as determined by the percent of total T cells that were CFSE low and producing interferon gamma (IFN&#x3b3;) in response to tumor antigen.</p><p id="p-0014" num="0013"><figref idref="DRAWINGS">FIG. <b>5</b></figref> depicts flow cytometry results for tumor specificity of MILs expanded under various conditions utilizing gates for CD3 and INF&#x3b3;. After seven days of expansion, 18.26% of MILs grown under hypoxic conditions were positive for both CD3 and interferon gamma. In contrast, only 1.72% of MILs grown under normoxic conditions were positive for both CD3 and interferon gamma.</p><p id="p-0015" num="0014"><figref idref="DRAWINGS">FIG. <b>6</b></figref> is a graph that depicts the in vivo expansion of lymphocytes post-autologous transplant including in subjects receiving MILs grown under various conditions. The x-axis corresponds to the number of days post-transplant and the y-axis corresponds to the average absolute lymphocyte count per microliter for the subjects. The graph suggests that MILs grown under hypoxic conditions continue to expand in human subjects more than MILs grown under only normoxic conditions.</p><p id="p-0016" num="0015"><figref idref="DRAWINGS">FIG. <b>7</b></figref> depicts flow cytometry results for MILs expanded under various oxygen conditions utilizing gates for CXCR4 and either CD4 or CD8. 28.38% of the total MILs population expanded under normoxic conditions were both CXCR4 positive and CD4 positive, with a mean fluorescence intensity of 3.9. 68.91% of MILs expanded under hypoxic conditions were both CXCR4 positive and CD4 positive, with a mean fluorescence intensity of 5.4. 8.02% of MILs expanded under normoxic conditions were both CXCR4 positive and CD8 positive, with a mean fluorescence intensity of 4.6. 11.08% of MILs expanded under hypoxic conditions were both CXCR4 positive and CD8 positive. These results suggest that hypoxia increases both the number of cells expressing CXCR4 as well as degree of expression per cell (MFI), which increases the likelihood of these cells to migrate to the bone marrow upon infusion.</p><p id="p-0017" num="0016"><figref idref="DRAWINGS">FIG. <b>8</b></figref> consists of three panels, labeled panels (A), (B), and (C). Panel A depicts flow cytometry results for peripheral blood lymphocytes (PBL) and MILs prior to cell expansion, utilizing gates for CD4, CD8, and 4-1BB. Panel B depicts flow cytometry results for PBLs and MILs following expansion under normoxic conditions, utilizing gates for CD4, CD8, and 4-1BB. As shown, 4-1BB expression in PBLs decreased in CD8 PBLs, from 11.34% to 0.34%, and MILs CD8 showed a decrease from 15.1% to 7.54%. Panel C depicts flow cytometry results for PBLs and MILs following expansion under hypoxic conditions, utilizing gates for CD4, CD8, and 4-1BB. PBLs downregulated 4-1BB following expansion under hypoxic conditions (CD8 PBLs: baseline 11.34% to 0%), whereas MILs upregulated 4-1BB following expansion under hypoxic conditions (CD8 MILs: baseline 15.1% to 21.79%).</p><p id="p-0018" num="0017"><figref idref="DRAWINGS">FIG. <b>9</b></figref> is a graph that shows that the growth of MILs under hypoxic conditions increases the number of CD3+ cells relative to growth under only normoxic conditions.</p><p id="p-0019" num="0018"><figref idref="DRAWINGS">FIG. <b>10</b></figref> shows flow cytometry results indicating that the expansion of MILs under hypoxic conditions results in a higher percentage of CD4<sup>+</sup>/4-1BB<sup>+</sup> cells than either expansion of PBLs under hypoxic conditions or the expansion of MILs under normoxic conditions.</p><p id="p-0020" num="0019"><figref idref="DRAWINGS">FIG. <b>11</b></figref> is a graph that shows the ex vivo expansion of MILs. MILs expanded under hypoxic conditions resulted in a larger dose relative to MILs expanded under only normoxic conditions.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0005" level="1">DETAILED DESCRIPTION</heading><p id="p-0021" num="0020">A major objective to achieve with adoptive T cell therapy is the ability to grow the largest number of tumor specific T cells that will subsequently also expand in vivo upon reinfusion and persist over time. In some aspects, the invention relates to a novel approach to T cell expansion that takes advantage of intrinsic properties of marrow infiltrating lymphocytes (&#x201c;MILs&#x201d;). Specifically, MILs significantly differ from peripheral lymphocytes (PBLs). For example, MILs are more easily expanded, upregulate activation markers to a greater extent than PBLs, maintain more of a skewed VP repertoire, traffic to the bone marrow, and most importantly, possess significantly greater tumor specificity. MILs anti-myeloma immunity correlates directly with clinical response; however, no in vivo T cell expansion or persistent clinical response has previously been observed following infusion.</p><p id="p-0022" num="0021">Culturing MILs at an O<sub>2 </sub>level of less than 21% oxygen, such as about 1% oxygen to about 7% oxygen or about 1% oxygen to about 3% oxygen, e.g., 2% oxygen (hypoxic conditions) increases both the overall expansion of the cells as well as their ability to recognize tumor cells relative to culturing in only normoxic conditions. Thus, in some embodiments, the invention relates to a method for the preparation of MILs for therapeutic use comprising one or more of the following. Bone marrow may be collected from a patient. The collected bone marrow may be frozen or immediately used, for example, to create tumor specific MILs. If the bone marrow is frozen, it is preferably thawed before incubation. The bone marrow may be treated to purify MILs through methods known to one of ordinary skill in the art. The MILs may be activated, for example, with beads, e.g., anti-CD3/CD28 beads. The ratio of beads to cells in the solution may vary; in some preferred embodiments, the ratio is 3 to 1. Similarly, the MILs may be expanded in the presence of one or more antibodies, antigens, and/or cytokines, e.g., in the absence of anti-CD3/CD28 beads. The cell count for the collected bone marrow may be determined, for example, to adjust the amount of beads, antibodies, antigens, and/or cytokines to be added to the MILs. In some embodiments, MILs are captured using beads specifically designed to collect the cells.</p><p id="p-0023" num="0022">The collected MILs are preferentially grown in a hypoxic environment, e.g., for a first period of time. In some embodiments, MILs may be placed in a tissue culture bag in X-VIVO&#x2122; 15 media supplemented with 2% AB serum and 200 U of IL2. It is contemplated that other culture conditions and elements may be used as recognized by a person of ordinary skill in the art. The MILs may be grown in an environment of about 1% to about 7% oxygen (hypoxia; hypoxic conditions), preferably about 1% to about 3% oxygen, such as about 2% oxygen, for about 3 to about 20 days (i.e., a first period of time), such as about 3 to about 10 days, such as 4 days. The hypoxic environment may be created, for example, by adding nitrous oxide to the container in which the cells are grown. In some embodiments, the hypoxic environment may be created by utilizing a hypobaric chamber. After the hypoxic growth, the MILs may be grown in a normoxic environment, e.g., 21% oxygen. In some preferred embodiments, the MILs are grown in normoxic conditions for an additional about 3 to about 7 days (i.e., a second period of time), e.g., for a total of about 3 to about 27 days of growth, such as about 3 to about 10 days growth. The grown cells may then be either administered to a patient (e.g., either the patient or an allogenic recipient) or stored for future use.</p><p id="p-0024" num="0023">MILs collected from the patient's bone marrow and treated in accordance with a method described herein, namely, under hypoxic conditions for a first period of time followed by normoxic conditions for a second period of time, perform unexpectedly better than peripheral blood lymphocytes (PBLs) subjected to the same procedure. The enhanced abilities of the MILs, as shown below, include marked expansion both in vitro and in vivo, enhanced expression of biological markers such as 4-1BB, and increased tumor specificity.</p><p id="p-0025" num="0024">A person of ordinary skill in the art would recognize that the procedure of the present invention can be utilized to treat many different types of cancer, including, myeloma, lung cancer, and breast cancer. As bone marrow is a reservoir of central memory cells, tumor specific T cells from any variety of cancers have been found in the bone marrow of patients. As disclosed herein, hypoxic culturing conditions increase both expansion as well as tumor specificity, and thus, this approach may be used to grow MILs from a wide range of cancer patients. In some preferred embodiments, a patient's MILs are collected, expanded in hypoxic conditions for a first period of time, e.g., for about 1 day to about 20 days, and then expanded in normoxic conditions for a second period of time, e.g., about 3 days to about 7 days. The cells may then be provided to the patient for treatment or stored for future use.</p><p id="p-0026" num="0025">In some aspects, the invention relates to the finding that expanding MILs in a hypoxic environment allows for in vivo T cell expansion following infusion. Specifically, MILs were grown in 2% O<sub>2 </sub>(hypoxia) for 3 days followed by a switch to 21% O<sub>2 </sub>(normoxia), resulting in almost a 10-fold greater tumor specificity (<figref idref="DRAWINGS">FIG. <b>4</b></figref>). Taken together, these data suggest that such growth conditions are capable of increasing the absolute number of tumor specific MILs obtained from the same source relative to MILs that a grown under only normoxic conditions.</p><p id="p-0027" num="0026">All experiments were performed using MILs products from patient samples. As shown in <figref idref="DRAWINGS">FIG. <b>3</b></figref>, expansion of a full scale clinical MILs product in hypoxic conditions dramatically increased T cell numbers. It should be noted that with normoxic conditions, it was difficult to expand MILs past 7 days. In this experiment, the day-7 expansion was 36.3 fold in normoxia versus 119 fold in hypoxia. Furthermore, the cells grown under hypoxic conditions continued to expand up to 12 days and reached a total 220-fold expansion at 11 days.</p><p id="p-0028" num="0027">In addition to obtaining better expansions and greater tumor specificity, growth conditions were optimized to maximize T cell survival. Expression of 4-1BB has been shown to be a key regulator of many of these properties. It can regulate T cell expansion, reduce apoptosis, augment the cytotoxic activity of CD8 cells, and enhance survival. Taken together, 4-1BB expression on activated MILs may be an important regulator of heightened survival and tumor specificity. Thus 4-1BB expression was examined on MILs and compared to that on PBLs grown in various conditions. As shown in <figref idref="DRAWINGS">FIG. <b>8</b></figref>, the baseline expression of 4-1BB was greater in MILs than PBLs (18.2% v 8.1%). Interestingly, T cell expansion in normoxia reduced its expression in both populations (MILs 10.7%, PBLs 2.8%) whereas expansion in hypoxia significantly increase 4-1BB expression in MILs (43.4%) and completely abrogated its expression in PBLs (0%). These data again underscore the significant differences between PBLs and MIL also demonstrate that 4-1BB upregulation depends upon more factors than simply hypoxic growth conditions.</p><p id="p-0029" num="0028">These culture conditions have been adopted to a clinical trial, and hypoxic growth conditions increased the total T cell expansion from an average of 7.9E9 to 1.8E10. Furthermore, hypoxic growth conditions also enabled the observation of in vivo T cell expansion (<figref idref="DRAWINGS">FIG. <b>6</b></figref>, which depicts the total lymphocyte counts through day 60 for all patients).</p><p id="p-0030" num="0029">In some aspects, the invention relates to a composition comprising marrow infiltrating lymphocytes (&#x201c;MILs&#x201d;). The MILs may be activated MILs.</p><p id="p-0031" num="0030">In preferred embodiments, the composition comprises a population of MILs that expresses CD3, i.e., wherein each cell in the population of MILs that expresses CD3 is a marrow infiltrating lymphocyte that expresses CD3, e.g., as detected by flow cytometry. For example, at least about 40% of the cells in the composition may be MILs from the population of MILs that express CD3, such as at least about 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, or even at least about 89% of the cells in the composition. In one preferred embodiment, at least about 80% of the cells in the composition may be MILs from the population of MILs that express CD3. In some embodiments, about 40% to about 100% of the cells in the composition may be MILs from the population of MILs that express CD3, such as about 45% to about 100%, about 50% to about 100%, about 55% to about 100%, about 60% to about 100%, about 65% to about 100%, about 70% to about 100%, about 75% to about 100%, about 80% to about 100%, about 85% to about 100%, about 86% to about 100%, about 87% to about 100%, about 88% to about 100%, or even about 89% to about 100% of the cells in the composition. In some embodiments, the composition comprises either a population of MILs that do not express CD3, e.g., as detected by flow cytometry, or a population of MILs that expresses low levels of CD3, i.e., relative to the expression level of MILs from the population of MILs that express CD3.</p><p id="p-0032" num="0031">In some embodiments, the composition comprises a population of MILs that expresses interferon gamma (&#x201c;IFN&#x3b3;&#x201d;), i.e., wherein each cell in the population of MILs that expresses IFN&#x3b3; is a marrow infiltrating lymphocyte that expresses IFN&#x3b3;, e.g., as detected by flow cytometry. For example, at least about 2% of the cells in the composition may be MILs from the population of MILs that express IFN&#x3b3;, such as at least about 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, or even at least about 18% of the cells in the composition. In some embodiments, about 2% to about 100% of the cells in the composition may be MILs from the population of MILs that express IFN&#x3b3;, such as about 2% to about 100%, about 3% to about 100%, about 4% to about 100%, about 5% to about 100%, about 6% to about 100%, about 7% to about 100%, about 8% to about 100%, about 9% to about 100%, about 10% to about 100%, about 11% to about 100%, about 12% to about 100%, about 13% to about 100%, about 14% to about 100%, about 15% to about 100%, about 16% to about 100%, about 17% to about 100%, or even about 18% to about 100% of the cells in the composition. In some embodiments, the composition comprises either a population of MILs that do not express IFN&#x3b3;, e.g., as detected by flow cytometry, or a population of MILs that expresses low levels of IFN&#x3b3;, i.e., relative to the expression level of MILs from the population of MILs that express IFN&#x3b3;.</p><p id="p-0033" num="0032">In some embodiments, the composition comprises a population of MILs that expresses CXCR4, i.e., wherein each cell in the population of MILs that expresses CXCR4 is a marrow infiltrating lymphocyte that expresses CXCR4, e.g., as detected by flow cytometry. For example, at least about 98% of the cells in the composition may be MILs from the population of MILs that express CXCR4, such as at least about 98.1%, 98.2%, 98.3%, 98.4%, 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99.0%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, or even at least about 99.7% of the cells in the composition. In some embodiments, about 98% to about 100% of the cells in the composition may be MILs from the population of MILs that express CXCR4, such as at least about 98.1% to about 100%, about 98.2% to about 100%, about 98.3% to about 100%, about 98.4% to about 100%, about 98.5% to about 100%, about 98.6% to about 100%, about 98.7% to about 100%, about 98.8% to about 100%, about 98.9% to about 100%, about 99.0% to about 100%, about 99.1% to about 100%, about 99.2% to about 100%, about 99.3% to about 100%, about 99.4% to about 100%, about 99.5% to about 100%, about 99.6% to about 100%, or even about 99.7% to about 100% of the cells in the composition. In some embodiments, the composition comprises either a population of MILs that do not express CXCR4, e.g., as detected by flow cytometry, or a population of MILs that expresses low levels of CXCR4, i.e., relative to the expression level of MILs from the population of MILs that express CXCR4.</p><p id="p-0034" num="0033">In some embodiments, the composition comprises a population of MILs that expresses CD4. The population of MILs that expresses CD4 may comprise a plurality of MILs that expresses CXCR4.</p><p id="p-0035" num="0034">The population of MILs that expresses CD4 may comprise a plurality of MILs that expresses 4-1BB. For example, at least about 21% of the cells in the composition may be MILs from the plurality of MILs that expresses 4-1BB, such as at least about 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, or even at least about 43% of the cells in the composition. In some embodiments, about 21% to about 100% of the cells in the composition may be MILs from the plurality of MILs that expresses 4-1BB, such as about 22% to about 100%, about 23% to about 100%, about 24% to about 100%, about 25% to about 100%, about 26% to about 100%, about 27% to about 100%, about 28% to about 100%, about 29% to about 100%, about 30% to about 100%, about 31% to about 100%, about 32% to about 100%, about 33% to about 100%, about 34% to about 100%, about 35% to about 100%, about 36% to about 100%, about 37% to about 100%, about 38% to about 100%, about 39% to about 100%, about 40% to about 100%, about 41% to about 100%, about 42% to about 100%, or even about 43% to about 100% of the cells in the composition.</p><p id="p-0036" num="0035">The composition may comprise a population of MILs that expresses CD8. The population of MILs that expresses CD8 may comprise a plurality of MILs that expresses CXCR4.</p><p id="p-0037" num="0036">The population of MILs that expresses CD8 may comprise a plurality of MILs that expresses 4-1BB. For example, at least about 21% of the cells in the composition may be MILs from the plurality of MILs that expresses 4-1BB, such as at least about 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20% or even at least about 21% of the cells in the composition. In some embodiments, about 2% to about 100% of the cells in the composition may be MILs from the plurality of MILs that expresses 4-1BB, such as about 8% to about 100%, about 9% to about 100%, about 10% to about 100%, about 11% to about 100%, about 12% to about 100%, about 13% to about 100%, about 14% to about 100%, about 15% to about 100%, about 16% to about 100%, about 17% to about 100%, about 18% to about 100%, about 19% to about 100%, about 20% to about 100%, or even about 21% to about 100% of the cells in the composition.</p><p id="p-0038" num="0037">In some embodiments, the composition comprises a population of MILs that expresses 4-1BB. For example, at least about 21% of the cells in the composition may be MILs from the population of MILs that expresses 4-1BB, such as at least about 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, or even at least about 43% of the cells in the composition. In some embodiments, about 21% to 100% of the cells in the composition may be MILs from the population of MILs that expresses 4-1BB, such as about 22% to about 100%, about 23% to about 100%, about 24% to about 100%, about 25% to about 100%, about 26% to about 100%, about 27% to about 100%, about 28% to about 100%, about 29% to about 100%, about 30% to about 100%, about 31% to about 100%, about 32% to about 100%, about 33% to about 100%, about 34% to about 100%, about 35% to about 100%, about 36% to about 100%, about 37% to about 100%, about 38% to about 100%, about 39% to about 100%, about 40% to about 100%, about 41% to about 100%, about 42% to about 100%, or even about 43% to about 100% of the cells in the composition. In some embodiments, the composition comprises either a population of MILs that do not express 4-1BB, e.g., as detected by flow cytometry, or a population of MILs that expresses low levels of 4-1BB, i.e., relative to the expression level of MILs from the population of MILs that express 4-1BB.</p><p id="p-0039" num="0038">In some aspects, the invention relates to a method for preventing or treating cancer in a subject, comprising administering to the subject any one of the compositions described herein. In preferred embodiments, the method comprises administering to the subject a therapeutically-effective amount of any one of the compositions described herein. In preferred embodiments, the method comprises administering to the subject a therapeutically-effective amount of MILs, e.g., activated MILs, as described herein. The subject may have a neoplasm, such as cancer. For example, the subject may have multiple myeloma. The subject may be a human subject.</p><p id="p-0040" num="0039">In some aspects, the invention relates to a method for making a composition as described herein, comprising incubating MILs in a hypoxic environment. In some aspects, the invention relates to a method for activating marrow infiltrating lymphocytes (&#x201c;MILs&#x201d;), comprising incubating MILs in a hypoxic environment.</p><p id="p-0041" num="0040">In some aspects, the invention relates to a method for method for treating cancer in a subject. The method may comprise removing marrow infiltrating lymphocytes (&#x201c;MILs&#x201d;) from the subject; incubating the MILs in a hypoxic environment, thereby producing activated MILs; and administering the activated MILs to the subject.</p><p id="p-0042" num="0041">The hypoxic environment may comprise less than about 21% oxygen, such as less than about 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, or less than about 3% oxygen. For example, the hypoxic environment may comprise about 0% oxygen to about 20% oxygen, such as about 0% oxygen to about 19% oxygen, about 0% oxygen to about 18% oxygen, about 0% oxygen to about 17% oxygen, about 0% oxygen to about 16% oxygen, about 0% oxygen to about 15% oxygen, about 0% oxygen to about 14% oxygen, about 0% oxygen to about 13% oxygen, about 0% oxygen to about 12% oxygen, about 0% oxygen to about 11% oxygen, about 0% oxygen to about 10% oxygen, about 0% oxygen to about 9% oxygen, about 0% oxygen to about 8% oxygen, about 0% oxygen to about 7% oxygen, about 0% oxygen to about 6% oxygen, about 0% oxygen to about 5% oxygen, about 0% oxygen to about 4% oxygen, or about 0% oxygen to about 3% oxygen. In preferred embodiments, the hypoxic environment comprises about 1% to about 7% oxygen. The hypoxic environment may comprise about 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or about 0% oxygen. In preferred embodiments, the hypoxic environment comprises about 7%, 6%, 5%, 4%, 3%, 2%, or 1% oxygen.</p><p id="p-0043" num="0042">Incubating MILs in a hypoxic environment may comprise incubating the MILs, e.g., in tissue culture medium, for at least about 1 hour, such as at least about 12 hours, 18 hours, 24 hours, 30 hours, 36 hours, 42 hours, 48 hours, 60 hours, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or even at least about 14 days. Incubating may comprise incubating the MILs for about 1 hour to about 30 days, such as about 1 day to about 20 days, about 1 day to about 14 days, or about 1 day to about 12 days. In some preferred embodiments, incubating MILs in a hypoxic environment comprises incubating the MILs in a hypoxic environment for about 2 days to about 5 days. The method may comprise incubating MILs in a hypoxic environment for about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 day, 9 days, 10 days, 11 days, 12 days, 13 days, or 14 days. In some preferred embodiments, the method comprises incubating the MILs in a hypoxic environment for about 3 days.</p><p id="p-0044" num="0043">In preferred embodiments, the method further comprises incubating the MILs in a normoxic environment, e.g., after incubating the MILs in a hypoxic environment.</p><p id="p-0045" num="0044">The normoxic environment may comprise at least about 21% oxygen. The normoxic environment may comprise about 5% oxygen to about 30% oxygen, such as about 10% oxygen to about 30% oxygen, about 15% oxygen to about 25% oxygen, about 18% oxygen to about 24% oxygen, about 19% oxygen to about 23% oxygen, or about 20% oxygen to about 22% oxygen. In some embodiments, the normoxic environment comprises about 21% oxygen.</p><p id="p-0046" num="0045">Incubating MILs in a normoxic environment may comprise incubating the MILs, e.g., in tissue culture medium, for at least about 1 hour, such as at least about 12 hours, 18 hours, 24 hours, 30 hours, 36 hours, 42 hours, 48 hours, 60 hours, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or even at least about 14 days. Incubating may comprise incubating the MILs for about 1 hour to about 30 days, such as about 1 day to about 20 days, about 1 day to about 14 days, about 1 day to about 12 days, or about 2 days to about 12 days.</p><heading id="h-0006" level="1">EXEMPLIFICATION</heading><heading id="h-0007" level="1">Example 1. Activation and Expansion of T Cells in Hypoxic and Normoxic Environments</heading><p id="p-0047" num="0046">Bone marrow (BM) T cell numbers are determined using flow cytometry. Anti-CD3/anti-CD28 beads are added at the pre-determined ratio (beads:CD3 cell) in media with recombinant human cytokines at a predetermined concentration. Cells are plated in a plate, flask, or bag. Hypoxic conditions are achieved by flushing either the hypoxic chamber or cell culture bag for 3 minutes with a 95% Nitrogen and 5% CO<sub>2 </sub>gas mixture. The receptacle is then filled with this gas mixture for 30 seconds. This leads to a 2% or less O<sub>2 </sub>gas in the receptacle. Cells are cultured at 37 C for 3 or more days and the hypoxic air is released and replaced with normoxic (21% atmospheric oxygen) levels.</p><heading id="h-0008" level="1">Example 2. Phenotypic Determination of Cell Types</heading><p id="p-0048" num="0047">Cells are stained with flurochrome conjugated antibodies for the desired determination. CD3, CD4, CD8, CXCR4, 41BB, CD27, CD28, CTLA-4, PD-1, CD45RO, CD62L, CD95, IFNg, IL17, live/dead dye, and/or other antibodies of interest that are directly conjugated to flurochromes are used with appropriate isotype controls. Briefly, 1&#xd7;10<sup>6 </sup>cells or less are washed with FACS buffer (1XHBSS/2% FBS/0.5% EDTA/0.5% NaAzide) or similar wash buffer in either a plate or a tube by spinning in a centrifuge. The wash buffer is removed and antibodies and isotype controls are added at predetermined concentrations. The cells are stained between 7-30 minutes at either room temperature or at 4&#xb0; C. The cells are washed 2&#xd7; with wash buffer and re-suspended in minimal wash buffer. The cells are then run on a flow cytometer that has been properly compensated and prepared for the flurochromes that are being utilized. 10,000 or greater numbers of events are collected for each sample. Data is analyzed utilizing FACS analysis software. Flurochrome labelled cells are compared to isotype controls for back ground removal. Data is graphed as % positive&#x2212;% background.</p><heading id="h-0009" level="1">Example 3. Determination of Fold Expansion</heading><p id="p-0049" num="0048">Bone marrow cells are enumerated at the beginning of expansion. The percentage of CD3+ cells is determined utilizing flow cytometry. The total number of CD3+ MILs is determined by multiplying the total number of cells with the percentage of CD3=total number of CD3+ MILs in culture. On the final day of culture the cells are harvested and counted (both manually and with an automated cell counter). The percentage of CD3+ is determined. The total number of CD3+ cells on the final day of culture is determined by multiplying total cell number with the percentage of CD+=total number of CD3+ MILs harvested. Total fold expansion=Total number of CD3+ MILs harvested on the final day of culture divided by the total number of CD3+ MILs on the initial day of culture.</p><heading id="h-0010" level="1">Example 4. Tumor Specificity</heading><p id="p-0050" num="0049">MILs are labelled with CFSE or a similar cell membrane integration dye according to the manufacturers' protocol. Autologous BM is pulsed with either media alone, a negative control (unrelated protein or lysate) or with the protein or lysate of interest. CFSE labelled cells are then co-cultured with pulsed autologous BM for 2-7 days. Cells are harvested from the tissue culture plate or flask and then stained with CD3 extracellularly and intracellularly with IFNg. Analysis of tumor specificity is determined by gating on CD3+ cells that are CFSE low (divided cells) and that are producing IFNg.</p><heading id="h-0011" level="1">Example 5. Activation and Expansion of T Cells in Hypoxic and Normoxic Environments</heading><p id="p-0051" num="0050">MILs were grown in 2% O<sub>2 </sub>(hypoxia) for 3 days followed by a switch to 21% O<sub>2 </sub>(normoxia) for an additional 5 days in the presence or absence of IL-2. As shown in <figref idref="DRAWINGS">FIG. <b>9</b></figref>, growth in hypoxia followed by normoxia resulted in almost a 10-fold increase in expansion as compared to MILs grown exclusively in normoxic conditions. Tumor specificity was also markedly enhanced as shown on <figref idref="DRAWINGS">FIG. <b>4</b></figref>. On day 10, 4% of CFSE-low cells were tumor specific in normoxic conditions as opposed to 25.1% for MILs grown in hypoxic conditions. Taken together, these data suggest that these growth conditions are capable of increasing the absolute number of tumor specific upon activation.</p><p id="p-0052" num="0051">The experiments in the preceding paragraph were performed on a small sample. MILs product from a patient in a first clinical study was also expanded using this method. As shown in <figref idref="DRAWINGS">FIG. <b>3</b></figref>, expansion of MILs in these conditions dramatically increased T cell numbers. Growth in normoxic conditions was seldom capable of expanding MILs past 7 days. In this experiment, the day-7 fold expansion was 36.3 fold in normoxic conditions as oppose to 119 in hypoxic conditions. Furthermore, the cells continued to expand up to 12 days and reached a total 220-fold expansion at 11 days before beginning to die.</p><p id="p-0053" num="0052">Expression of 4-1BB has been shown to be a key regulator of many of these properties. It can regulate T cell expansion, reduce apoptosis, augment the cytotoxic activity of CD8 cells and enhances survival. Furthermore, HIF1&#x3b1; regulates survival of antigen-driven T cells. Chimeric antigen receptor (CAR) modified T cells with the vector expressing 4-1BB have shown significant in vivo expansion. Taken together, 4-1BB expression on activated MILs can be an important regulator of heightened survival and tumor specificity. One marked advantage of the method disclosed herein is that there is no need to modify the MILs in order to achieve 4-1BB enhanced expression. This advantage is shown in <figref idref="DRAWINGS">FIG. <b>10</b></figref> where MILs or PBLs were grown in either normoxic or hypoxic conditions. Baseline expression of 4-1BB was evaluated in MILs and compared to PBLs. As shown, 4-1BB expression was greater in MILs than PBLs (18.2% v 8.1%). Interestingly, T cell expansion in normoxia reduced its expression in both populations (MILs 10.7%, PBLs 2.8%) whereas expansion in hypoxia significantly increases 4-1BB expression in MILs (43.4%) and completely abrogated its expression in PBLs (0%). These data again underscore the significant differences between PBLs and MIL also demonstrates that 4-1BB upregulation depends upon more factors than simply hypoxic growth conditions. More importantly, the unexpected upregulation of 4-1BB demonstrates that the method of the present invention makes a significant difference in the treatment of patients using hypoxically grown MILs. Similar results were observed with CD8 cells (<figref idref="DRAWINGS">FIG. <b>8</b></figref>).</p><p id="p-0054" num="0053"><figref idref="DRAWINGS">FIG. <b>11</b></figref> shows the results of dosing for clinical treatment. In J0770, MILs were grown in static cultures in normoxic conditions. J0997&#x2014;MILs were grown in the WAVE in normoxic conditions. J1343&#x2014;MILs were grown for 3 days in hypoxic conditions followed by normoxic conditions. In <figref idref="DRAWINGS">FIG. <b>6</b></figref> the absolute lymphocyte counts are graphed for the 3 trials post-autologous stem cell transplant. J1343 is a randomized trial in which patients either received hypoxic MILs or had no MILs infused post-transplant.</p><p id="p-0055" num="0054">As shown in <figref idref="DRAWINGS">FIG. <b>11</b></figref>, the growth conditions of the present method have increased total T cell expansion from an average of 7.9E9 to 1.8E10. Furthermore, it shows for the first time in vivo T cell expansion as shown in <figref idref="DRAWINGS">FIG. <b>6</b></figref>, which is directly related to the efficacy of the method in treatment of patients. Depicted in the graph are the total lymphocyte counts through day 60 for a first set of patients.</p><heading id="h-0012" level="1">EQUIVALENTS</heading><p id="p-0056" num="0055">Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.</p><?detailed-description description="Detailed Description" end="tail"?></description><claims id="claims"><claim id="CLM-01-11" num="01-11"><claim-text><b>1</b>-<b>11</b>. (canceled)</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. A method for making a composition comprising a population of marrow infiltrating lymphocytes (&#x201c;MILs&#x201d;), comprising incubating the MILs in an environment comprising less than 21% oxygen, wherein the composition comprises a population of MILs that expresses CD3; and at least about 40% of the cells in the composition are MILs from the population of MILs that expresses CD3.</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. A method for activating marrow infiltrating lymphocytes (&#x201c;MILs&#x201d;), comprising incubating MILs in an environment comprising less than 21% oxygen.</claim-text></claim><claim id="CLM-14-34" num="14-34"><claim-text><b>14</b>-<b>34</b>. (canceled)</claim-text></claim><claim id="CLM-00035" num="00035"><claim-text><b>35</b>. A marrow infiltrating lymphocyte (MIL) formulation, comprising a composition of a population of MILs prepared by the method of <claim-ref idref="CLM-00012">claim 12</claim-ref>.</claim-text></claim><claim id="CLM-00036" num="00036"><claim-text><b>36</b>. A therapeutically effective marrow infiltrating lymphocyte (MIL) formulation grown under hypoxic conditions in vitro.</claim-text></claim><claim id="CLM-37-38" num="37-38"><claim-text><b>37</b>-<b>38</b>. (canceled)</claim-text></claim><claim id="CLM-00039" num="00039"><claim-text><b>39</b>. The method of <claim-ref idref="CLM-00012">claim 12</claim-ref>, wherein the composition comprises a population of MILs that expresses interferon gamma (&#x201c;IFN&#x3b3;&#x201d;); and at least about 2% of the cells in the composition are MILs from the population of MILs that expresses IFN&#x3b3;.</claim-text></claim><claim id="CLM-00040" num="00040"><claim-text><b>40</b>. The method of <claim-ref idref="CLM-00012">claim 12</claim-ref>, wherein the population of MILs that expresses CD3 comprises a plurality of MILs that expresses interferon gamma (&#x201c;IFN&#x3b3;&#x201d;); and at least about 2% of the cells in the composition are MILs from the plurality of MILs that expresses IFN&#x3b3;.</claim-text></claim><claim id="CLM-00041" num="00041"><claim-text><b>41</b>. The method of <claim-ref idref="CLM-00012">claim 12</claim-ref>, wherein the composition comprises a population of MILs that expresses CXCR4; and at least about 98% of the cells in the composition are MILs from the population of MILs that expresses CXCR4.</claim-text></claim><claim id="CLM-00042" num="00042"><claim-text><b>42</b>. The method of <claim-ref idref="CLM-00012">claim 12</claim-ref>, wherein the composition comprises a population of MILs that expresses CD4.</claim-text></claim><claim id="CLM-00043" num="00043"><claim-text><b>43</b>. The method of <claim-ref idref="CLM-00042">claim 42</claim-ref>, wherein the population of MILs that expresses CD4 comprises a plurality of MILs that expresses CXCR4; and at least about 98% of the cells in the composition are MILs from the plurality of MILs that expresses CXCR4.</claim-text></claim><claim id="CLM-00044" num="00044"><claim-text><b>44</b>. The method of <claim-ref idref="CLM-00042">claim 42</claim-ref>, wherein the population of MILs that expresses CD4 comprises a plurality of MILs that expresses 4-IBB; and<claim-text>at least about 21% of the cells in the composition are MILs from the plurality of MILs that expresses 4-IBB.</claim-text></claim-text></claim><claim id="CLM-00045" num="00045"><claim-text><b>45</b>. The method of <claim-ref idref="CLM-00012">claim 12</claim-ref>, wherein the composition comprises a population of MILs that expresses CDS.</claim-text></claim><claim id="CLM-00046" num="00046"><claim-text><b>46</b>. The method of <claim-ref idref="CLM-00045">claim 45</claim-ref>, wherein the population that expresses CDS comprises a plurality of MILs that expresses CXCR4; and at least about 98% of the cells in the composition are MILs from the plurality of MILs that expresses CXCR4.</claim-text></claim><claim id="CLM-00047" num="00047"><claim-text><b>47</b>. The method of <claim-ref idref="CLM-00045">claim 45</claim-ref>, wherein the population of MILs that expresses CDS comprises a plurality of MILs that expresses 4-IBB; and at least about 21% of the cells in the composition are MILs from the plurality of MILs that expresses 4-IBB.</claim-text></claim><claim id="CLM-00048" num="00048"><claim-text><b>48</b>. The method of <claim-ref idref="CLM-00012">claim 12</claim-ref>, wherein the composition comprises a population of MILs that expresses 4-IBB; and at least about 21% of the cells in the composition are MILs from the population of MILs that expresses 4-IBB.</claim-text></claim></claims></us-patent-application>